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ABSTRACT OF THE DISSERTATION 
Linking Neuronal Protein Phosphatase 2A to the DLK Stress Kinase Signaling Cascade  
by 
Margaret Hayne 
Doctor of Philosophy in Biology and Biomedical Sciences 
Neurosciences 
Washington University in St. Louis, 2021 
Professor Aaron DiAntonio, Chair 
 Neurons are constantly responding to internal and external cues as they adapt through 
signaling cascades and transcriptional programs. I have identified a role for the dual leucine 
zipper kinase (DLK) and the transcriptional program it controls in neuronal inhibition of the 
protein phosphatase PP2A. PP2A is an essential phosphatase, expressed in all cell types and 
required for survival. There is a reduction in PP2A activity in Alzheimer’s disease patient brains 
which is linked to increased phosphorylation of the microtubule associated protein Tau and 
ultimately cell death. Here, I have demonstrated that PP2A acts to restrain the DLK stress 
response and that DLK signaling is required for both developmental and degenerative 
phenotypes from PP2A inhibition. At the Drosophila neuromuscular junction loss of PP2A 
activity causes synaptic overgrowth which requires DLK signaling and induction of a 
downstream transcriptional response.   Further, DLK is also required for neuronal cell death 
following PP2A inhibition in mammalian cortical neurons in vitro.  Importantly, DLK signaling 
does not affect the phosphorylation of Tau and, indeed, this neuronal cell death is demonstrated 









Chapter 1: Introduction 
Neurons are post-mitotic cells, meaning that they must survive for the entirety of an 
organism’s lifespan as they will not be replaced through cell division. To do this, they must sense 
both internal and external cues and respond appropriately. This sensing and the downstream 
responses are often carried out by signaling cascades which converge with either post-translational 
modifications to proteins or transcriptional alterations, increasing or decreasing transcription of 
target genes. Here, I will explore the links between a protein phosphatase and the activation of a 
stress signaling cascade in both peripheral and central neurons, with implications for disease 
treatment. 
1.1 DLK controls a neuronal stress signaling cascade 
The mitogen-activated protein kinase kinase kinase (MAP3K) dual zipper leucine kinase 
(DLK) plays an evolutionarily conserved role in neuronal development. In C. elegans DLK is 
referred to as DLK-1 and the Drosophila ortholog is called Wallenda (Wnd)(Collins et al., 2006; 
Nakata et al., 2005). DLK as a MAP3K activates MAP2Ks, in this case MKK4 and MKK7, and 
the MAP kinase Jun-activated N-terminal kinase (JNK)(Walker et al., 2017). This cascade 
ultimately activates the transcription factors Fos and Jun when turning on a transcriptional program 
in the cell body(Collins et al., 2006).  
Knockdown of DLK in cultured primary cortical neurons resulted in decreased extension 
of neurites(Eto et al., 2010). DLK knockout mice also displayed defects in the developing cortex, 
thought to be linked to a similar mechanism(Hirai et al., 2006). Because migrating neurons travel 
along an extended axon to their final location in the cortex, it is thought that the improper axon 




 While there are some effects of DLK and its orthologues in development, the best-studied 
role for DLK is in neuronal stress responses. DLK is typically activated in the axons, long 
processes extending from the cell bodies which must be maintained and respond appropriately 
when injured(Asghari Adib et al., 2018). Upon activation, DLK sends a retrograde signal to the 
cell body, where a transcriptional program is activated(Xiong et al., 2010a). This transcriptional 
program depends on the organism, cell type, and severity of DLK activation(Asghari Adib et al., 
2018; Collins et al., 2006; Watkins et al., 2013). 
1.1.1 Regeneration 
 In the peripheral nervous system, DLK signaling in an injured neuron tends to be pro-
regenerative. An injured neurite will attempt to grow outward and reform synaptic connections 
following an injury, which requires a DLK-dependent transcriptional program to be activated. In 
C. elegans with axons severed by lasers, there are no growth cones observed in DLK-1 mutant 
animals 5 days after injury while wildtype animals have observable growth cones only 24 hours 
following laser axotomy(Hammarlund et al., 2009a). In Drosophila peripheral nerve injury 
requires DLK for increased axonal sprouting following injury. This pinch injury, which injures the 
nerves in an intact larva, also induces a DLK-dependent transcriptional program, measured using 
a LacZ enhancer trap for the phosphatase puckered (PucLacZ)(Xiong et al., 2010b). This role for 
regeneration is conserved in mammals, wherein mice lacking DLK in neurons with crushed sciatic 
nerves show reduced growth three days after injury compared to wildtype animals(Shin et al., 
2012a). Additionally, when a neurite is injured, the neuron turns on a DLK-dependent 
transcriptional program that dramatically enhances regrowth following a second injury in both 





When a neurite is injured the distal axon degenerates and the proximal axon is able to 
regenerate. Both of these processes involve DLK signaling. The olfactory neurons in adult 
Drosophila extend into the antennae, which as an exterior structure can be easily removed, and the 
axons extending into the brain can be imaged for degeneration. Loss of DLK/Wnd in these flies 
inhibits olfactory neuron axon degeneration for 24 hours, by which time wildtype axons have 
degenerated significantly(Miller et al., 2009). Dorsal root ganglion (DRG) neurons cultured from 
mouse embryos also display delayed axon degeneration following an insult, either a cut to sever 
the axons from the cell body or treatment with the chemotherapeutic vincristine, that was delayed 
in neurons from DLK mutant animals(Miller et al., 2009). 
 DLK activation is also required for neuronal cell death in a number of contexts. Embryonic 
DRG neurons undergo apoptosis following nerve growth factor (NGF) withdrawal in culture, but 
do not die if they lack DLK(Ghosh et al., 2011). Neuronal knockout of DLK also blocks cell death 
in retinal ganglion cells following a crush injury to the optic nerve and excitotoxicity models 
following kainic acid injections in the mouse brain(Pozniak et al., 2013b; Watkins et al., 2013; 
Welsbie et al., 2019).   
1.1.3 Development  
DLK can be activated extraneously during development, leading to a host of aberrations in 
the nervous system. An overabundance of DLK-1 in C. elegans causes alterations in the synaptic 
structure, seen by a reduction in the number of presynaptic synaptobrevin puncta as well as changes 
to their clustering patterns(Collins et al., 2006; Nakata et al., 2005). In Drosophila, increased 
DLK/Wnd activity leads to overgrowth of the presynaptic nerve terminal at neuromuscular 




of axons in the central nervous system(Collins et al., 2006; Goel and Dickman, 2018; Shin and 
DiAntonio, 2011). These changes are thought to result from the DLK stress signaling cascade 
being activated in an otherwise healthy neuron, triggering a regeneration response which alters the 
structure of the cells.   
1.1.4  Disease   
 The DLK stress pathway has been shown to have increased signaling and deleterious 
effects in several disease models. DLK/Wnd has also been demonstrated to be a key modulator of 
pathology in a fragile X syndrome Drosophila model. This is a developmental disease wherein 
patients display intellectual disability from impaired activity of an RNA repressing protein which 
was found to repress DLK/Wnd expression as a key target(Russo and DiAntonio, 2019). The 
dysregulation of transactive response DNA binding protein 43 (TDP-43) is a common feature of 
amyloid lateral sclerosis (ALS), a progressive neurodegenerative disease. In flies overexpressing 
TDP-43, neurodegeneration is blocked by a reduction in Wnd/DLK levels, although a complete 
knockout of Wnd/DLK enhances neurodegeneration(Zhan et al., 2015).   
Aberrant DLK activation is also observed in mammalian models of neurodegenerative 
disease. Subarachnoid hemorrhage in rats causes cell death and behavioral deficits which are 
reduced in animals with reduced DLK. An increase in DLK expression following subarachnoid 
hemorrhage was also observed, indicating that the insult triggered an aberrant increase in DLK 
signaling which contributed to pathology(Yin et al., 2017). In mice expressing PS2APP, presenilin 
2 (PSEN2) and amyloid precursor protein (APP), TauP301L, or superoxide dismutase 1 with a G93A 
mutation (SOD1G93A), all of which are human genes with disease-linked mutations for Alzheimer’s 
disease (PS2APP and TauP301L) or ALS (SOD1G93A) there is an increase in DLK signaling and 




in behavioral assays, and an increase in phosphorylation of the transcription factor Jun (p-Jun), a 
readout of cellular stress. Neuronal knockdown of DLK in all three of these neurodegenerative 
disease models blocked cell death, improved behavior readouts, and reduced levels of p-Jun. The 
increase in p-Jun indicates that these disease models are increasing DLK signaling, which is 
corroborated by an increase in p-Jun and p-JNK in the central nervous systems of ALS and AD 
patients(Le Pichon et al., 2017). Taken together, these studies suggest that DLK presents a 
druggable target for multiple neurodegenerative diseases.  
1.1.5  Control and Activation 
 The deleterious effects of overactivation of DLK signaling imply the need for a tight 
control of this signaling cascade. DLK levels are restrained by ubiquitination and subsequent 
protein degradation through the PHR (Pam/highwire/RPM-1) family of E3 ubiquitin 
ligases(Collins et al., 2006; Nakata et al., 2005). These ligases form complexes into an SCF 
ubiquitin ligase containing a single protein each from the cullin, SKP1, and f-box protein 
families(Brace et al., 2014). In worms, regulator of presynaptic morphology 1 (RPM-1) is a 
ubiquitin ligase that targets DLK-1 for degradation, animals mutant for RPM-1 have an 
overabundance of DLK-1 which is results in altered synaptic formation(Nakata et al., 2005). 
Drosophila Highwire (Hiw) similarly targets Wnd for degradation and mutants display synaptic 
and axonal phenotypes(Collins et al., 2006). PHR1, the mouse homologue of human Pam, -mutant 
mice have disrupted synapse formation that results in failure to properly form synapses through 
the phrenic nerve onto the diaphragm, leading to lethality with mice being unable to 
breathe(Burgess et al., 2004). Loss of other components of the SCF complex forming the ubiquitin 
ligase also result in altered synaptic development, such as SKPA identified as the key SKP1 




is also modulated by the chaperone protein HSP90 in flies and mice, as well as by post-translational 
modifications including palmitoylation(Holland et al., 2016; Karney-Grobe et al., 2018).  
 PHR complexes also target Nicotinamide Nucleotide Adenylyltransferase 2 (NMNAT2) 
for degradation(Xiong et al., 2012). NMANT2 has been defined to play an important role in the 
SARM1-mediated axon degeneration pathway as a labile protein that converts NMN to NAD, an 
essential ratio to maintain in order to keep SARM1 in an inhibited state(Figley et al., 2021; Gerdts 
et al., 2016). Additionally, high levels of NMNAT2 in Drosophila hiw mutants alter presynaptic 
release while having no effect on gross presynaptic morphology(Russo et al., 2019). These links 
between PHR proteins, NMNAT2, and DLK were further defined by Walker, et al. through 
demonstration that increased DLK activity also decreases NMNAT2 levels(Walker et al., 2017). 
These intertwining effects of PHR proteins on DLK and NMNAT2 and between DLK and 
NMNAT2 themselves continues to be a rich area of research, exploring how exactly these 
pathways contribute to axon degeneration and neuronal development.  
 Endogenous DLK has been shown to be activated not only by direct insults to neurites, 
such as axotomy, but also by dysregulation of the cytoskeletal structure. Treating cultured DRG 
neurons with either nocodazole, a drug that destabilizes microtubules, or cytochalasin D, which 
affects actin polymerization, results in an increased p-Jun in cell bodies. This is a DLK-dependent 
process, as neurons without DLK do not show this increase. The pharmaceuticals only increased 
DLK signaling when placed on neurites, treating the cell bodies had no effect on p-Jun 
levels(Valakh et al., 2015a). This effect of DLK activation following cytoskeleton disruption has 
also been demonstrated genetically in Drosophila, where mutation of the spectraplakin short stop, 
which acts to coordinate microtubules and actin – a process that will be discussed more thoroughly 




and actin, causes DLK-dependent synaptic overgrowth(Valakh et al., 2013). Neither of these 
manipulations affect DLK levels, but there is a change in downstream transcriptional program 
activation. Together, these studies demonstrate two cases in which altering the cytoskeleton of 
neurons activates a DLK-dependent transcriptional program responsible for downstream 
phenotypes and imply that other manipulations to the cytoskeleton will also activate DLK 
signaling in a potentially deleterious manner.  
1.2  Neuronal Cytoskeleton 
 The cytoskeleton is a dynamic structure that is constantly changing to function with a cell. 
During neuronal development the actin, microtubule, and neurofilament structure is necessary 
for proper structural support, neurite outgrowth, and organization of synaptic 
connections(Akhmanova and Steinmetz, 2010; Desai and Mitchison, 1997; Kapitein and 
Hoogenraad, 2015). DLK and PP2A, proteins highlighted in the other sections of this 
introduction, both interact with and are influenced by the neuronal cytoskeleton. Hence, here I 
will give a brief overview of cytoskeleton form and function in neurons.  
1.2.1 Building microtubule structure 
 Microtubules are a polymerized tube of polarized tubulin dimers, with a dynamic plus-end where 
dimers are added or removed under control of microtubule associated proteins 
(MAPs)(Akhmanova and Steinmetz, 2015). The constant growth and retraction of microtubules 
allow for exploration in space and retraction if a suitable environment is not found. Free tubulin 
binds GTP, which is hydrolyzed upon incorporation into the polymer structure. Because of this 
there is a GTP cap at the plus end of microtubules, where there is an abundance of recently 
incorporated tubulin that has not yet hydrolyzed the GTP to GDP(Kapitein and Hoogenraad, 




both end-binding (EB) proteins, which have intrinsic +TIP abilities, and other proteins that 
associate with EB proteins rather than the plus-end itself(Honnappa et al., 2009).  
 Because neurons are post-mitotic cells, proteins involved in centromere formation for cell cycle 
progression are instead sequestered in the cytoplasm and play a role in nucleation of neurite 
microtubules(Kuijpers and Hoogenraad, 2011). Existing microtubules can also be severed to 
create new microtubule structures by one of three major groups microtubule severing enzymes, 
katanin, spastin, or fidgetin. These proteins are important for neurite branching and outgrowth, 
similar processes to those observed in DLK-dependent axon regeneration(Mcnally and Roll-
Mecak, 2018). Indeed, Katanin depletion in Drosophila neurons results in an increase in the 
number of synaptic boutons at the larval NMJ(Yu et al., 2008).  
1.2.2Maintaining microtubule structure 
 There are four major types of MAPs, EB proteins, +TIPs, -TIPs, and MAPs which bind to 
polymerized microtubules and help maintain their stability(Desai and Mitchison, 1997). Tau, and 
other structural MAPs which fall into this fourth category such as MAP1 and MAP2 bind to 
microtubules and help to prevent microtubule catastrophe and depolymerization. Sequestration 
of these proteins in the cytoplasm increases depolymerization events(Rolls et al., 2021). 
Interestingly, all three of these proteins are targets of PP2A which will be discussed in the next 
section.      
1.2.3 Membrane-associated periodic structure  
 Coordination between actin and microtubules has long been appreciated as important for 
extending neurites, but since the advent of stochastic optical resolution microscopy scientists 
have been able to study the unique, repeating structure formed by actin and cytoskeletal proteins 




the length of the axon(Xu et al., 2013). A similar structure had been previously defined in 
erythrocytes, involving spectrin, ankyrin, and adducin proteins(Baines, 2010; Bennett and 
Baines, 2001). In neurons, this repeating pattern, termed the membrane-associated periodic 
structure appears to be axon-specific(Xu et al., 2013). 
 Interestingly, ankyrin, alpha- and beta-spectrin, and adducin, all proteins that are configured in 
this period actin structure, also show synaptic defects at the Drosophila NMJ when they are 
dysregulated. Loss of presynaptic adducin at the fly NMJ triggers synaptic overgrowth, as well 
as signs of synaptic retractions which indicated a neuronal dying-back phenotype(Pielage et al., 
2011). Loss of Ankyrin 2 in fly neurons also leads to retractions, but overexpression causes 
synaptic overgrowth and an increase in extraneous satellite boutons(Pielage et al., 2008). Loss of 
either presynaptic alpha- or beta-spectrin at the NMJ also causes retractions and disorganization 
of microtubules(Pielage et al., 2005). Taken together, alterations to the synaptic structure, a 
dysregulation of the cytoskeleton, and neurodegeneration all provide clear links to DLK 
signaling. These patterns of synaptic dysregulation that appears similar to aberrant DLK 
signaling hints that DLK may be sensitive to loss of the membrane-associated periodic structure 
in axons.          
1.3  Protein Phosphatase 2A 
Protein phosphatase 2A (PP2A) is an essential protein expressed in every cell in the 
body(Taleski and Sontag, 2018). Here, I will describe the basic biological processes PP2A is 
involved in, a more in-depth exploration of roles PP2A plays in neurons, and will end by discussing 
the links between PP2A and microtubule associated protein Tau and Alzheimer’s disease. In my 
thesis work I have tested the hypothesis that one of the crucial roles of PP2A in neurons is to 




processes will contribute to some of the deleterious effects of PP2A inhibition discussed in this 
section.   
1.3.1  PP2A biology 
Cells use post-translational modifications to regulate protein localization and activation. 
One of these common post-translational modifications is phosphorylation, which is added to a 
protein via kinase activity and removed through a phosphatase, such as PP2A. PP2A is a 
holoenzyme consisting of three subunits, a catalytic subunit (PP2A-C), as well as an A and a B 
regulatory subunit. PP2A activity is controlled not only by regulatory subunits, but also by post-
translational modifications(Janssens and Goris, 2001). Phosphorylation of PP2A inhibits activity, 
although PP2A appears to be capable of auto-dephosphorylation following these events(Chen et 
al., 1992). The catalytic subunit of PP2A can also be methylated to decrease substrate binding, 
with a methyl group being added by leucine carboxyl methyltransferase 1 (LCMT-1) and removed 
by protein phosphatase methyl transferase (PME-1)(Park et al., 2018; Sontag et al., 2004).  
 A complete loss of PP2A function is lethal, as PP2A is required for cell division. 
Drosophila mutant for PP2A-C cannot exit mitosis and display condensed chromosomes, an 
overabundance of centromeres, and disorganized microtubule spindles(Snaith et al., 1996). In 
Xenopus eggs this mitotic disorganization was expanded on and better defined to be the result of 
hyperphosphorylation of the microtubule associated protein Stathmin(Cormier et al., 1991). PP2A 
subunits have been shown to be dysregulated in a number of cancers and are thought to provide a 
potential target for chemotherapies(Janssens and Goris, 2001).  
1.3.2  PP2A in neurons 
PP2A is highly expressed in the brain, even after the point in development when expression 




pharmaceutical treatments. One of the most common chemical inhibitors of PP2A is okadaic acid 
(OA), but other protein phosphatases are inhibited along with PP2A so in the work discussed in 
Chapter 2 of this thesis I will use an alternative, more specific chemical inhibitor as well as test 
whether genetic inhibition of a related phosphatase give similar phenotypes as a control for any 
contamination of function in previous reports(Janssens and Goris, 2001).  
Cytoskeleton interactions 
 In neurons PP2A is strongly associated with the cytoskeleton, directly binding 
microtubules as well as modulating the activity of cytoskeleton-modifying proteins. PP2A directly 
binds purified tubulin, especially associating with microtubules that have been polymerized. This 
association leads to a reduction in PP2A activity compared to PP2A localized to the cytosol. 
Inhibition of PP2A activity leads to a reduction in microtubule stability and ultimately 
degeneration of the axon, likely through increased phosphorylation of MAPs as these are major 
PP2A substrates in neurons(Sontag et al., 1999). Taken together, these data support a model 
wherein stable microtubules create a negative feedback loop such that PP2A is less active and 
ultimately the microtubules will become less stable following increased phosphorylation of MAPs. 
PP2A will then detach from the depolymerizing microtubules, becoming available to act on MAPs 
in the cytosol to increase microtubule stability. This loop helps maintain the cytoskeleton as a 
dynamic cellular structure, constantly extending and retracting.  
 PP2A also helps to regulate the transport and function of neurofilaments. Neurofilament 
proteins make up a large portion of the structure in the axonal compartment, with some studies 
estimating that they make up more than 60% of the protein in the axoplasm. Neurofilaments 
interact with microtubules to coordinate the structural support and asymmetric organization of the 




with neurofilaments in white matter lysates. Hyperphosphorylation of neurofilaments following 
PP2A inhibition with OA disrupts anterograde transport of neurofilaments and disrupts axonal 
cytoskeletal structure(Saito et al., 2002; Strack et al., 1997).  
Microtubule associated proteins 
 PP2A directly binds MAPs as substrates, including the microtubule stabilizing proteins 
MAP2 and Tau(Janssens and Goris, 2001; Sontag and Sontag, 2014). PP2A specifically targets 
MAP2 at threonine 220, a common target of protein kinase A (PKA). When MAP2 is 
dephosphorylated at this site, it binds microtubules significantly more than when 
phosphorylated(Alexa et al., 2002). PP2A also binds to the microtubule binding region of MAP2, 
indicating that it specifically targets cytosolic substrate rather than that bound to and stabilizing 
microtubules(Sontag et al., 2012). Thus, PP2A activity on MAP2 promotes cytoskeletal stability 
through increased binding of MAP2 to microtubules following dephosphorylation.  
MAP1B is highly phosphorylated at a defined group of sites by proline-directed protein 
kinases during axonal elongation in development, but is then dephosphorylated following 
synaptogenesis(Ulloa et al., 1993). MAP1B is also phosphorylated at a second set of sites later in 
development by casein kinase II to modulate neuron outgrowth and microtubule dynamics(Gong 
et al., 2000b). Both sets of phosphorylation sites on MAP1B are efficiently targeted by PP2A 
despite interacting with different kinases and at different points in development.  
 PP2A targets the MAP doublecortin, a key modulator of axon outgrowth. Doublecortin 
localizes to the growing neurite tips and loss of Doublecortin results in unregulated migration of 
cortical neurons. Human mutations in Doublecortin cause the developmental disorder X-linked 




dissociation of Doublecortin from the extending process of neurites, indicating dephosphorylation 
of Doublecortin is a key mechanism in localization(Schaar et al., 2004).  
 Inhibition of PP2A in developing neurons leads to deleterious effects. Our lab has 
established that loss of PP2A function in Drosophila larval neurons causes synaptic overgrowth 
and dysregulation of active zone development(Viquez et al., 2009). Viquez et al., went on to 
demonstrate that the glycogen synthase kinase 3β (GSK-3β) acts antagonistically to PP2A in these 
phenotypes and that PP2A inhibition is affecting the neuronal cytoskeleton. The authors 
hypothesized that these changes were the direct result of cytoskeletal dysregulation, but in Chapter 
2 I will test the alternative hypothesis that PP2A inhibition activates a DLK-dependent 
transcriptional program required for the downstream phenotypes.    
1.3.3  PP2A, Tau, and Alzheimer’s disease 
Alzheimer’s disease (AD) is the most common form of dementia. It is characterized by 
extracellular amyloid beta plaques and abnormally phosphorylated forms of the MAP Tau in 
intracellular aggregates. Both of these proteins have been highly studied for pharmaceutical 
treatments that reduce their pathological formation or levels of the proteins themselves. Tau is a 
well-defined target of PP2A wherein loss of PP2A leads to hyperphosphorylation of Tau(Sontag 
and Sontag, 2014). Here, I will discuss the effects of lowered PP2A activity in AD patients with 
the implication that targeting a pathway downstream of this to reduce these effects provides a 
therapeutic target worthy of further investigation.  
Tau function and phosphorylation 
 Tau is a microtubule associated protein that helps to stabilize the cytoskeleton. The 
phosphorylation status of Tau modulates its function, with a lower number of phosphorylation 




AD, is sequestered in the cytoplasm and forms paired helical filaments (PHF) that ultimately 
contribute to intracellular tangles(Merrick et al., 1997). Tau binds to microtubules with C-terminal 
microtubule-binding motifs while the N-terminal projects into the cytoplasm to interact with 
MAPs or the plasma membrane. Tau is phosphorylated by multiple kinases, including GSK-3β, 
cdk5, PKA, and CaMKII at defined amino acid residues(Martin et al., 2011). The major 
phosphatase affecting these residues is PP2A, accounting for over 70% of Tau phosphatase activity 
in the human brain(Liu et al., 2005). Importantly, PP2A is highly efficient at dephosphorylating 
the pathogenic site serine 262, which will be used as a readout of Tau hyperphosphorylation in 
Chapter 2.  
PP2A inhibition in Alzheimer’s disease  
 There is a significant decrease in PP2A activity in AD patients, thought to contribute to the 
hyperphosphorylation of Tau. In one study of homogenate from patient brains there was a roughly 
20 to 40% drop in phosphatase activity modulating Tau status compared to control brains(Gong et 
al., 1995). When examining protein levels of PP2A in patient homogenate Sontag et al. found a 
decrease in the frontal and temporal cortex of AD patients compared to controls but did not find 
any changes in PP2A levels in the cerebellums of patient brains. These changes in protein levels 
correlate with decreased PP2A activity from patient brain homogenate(Sontag et al., 2004). The 
catalytic subunit of PP2A was found to be significantly lowered in a cDNA library of the cingulate 
cortex and amygdala tested by microarray as well as in mRNA levels in the hippocampus for AD 
patient brains compared to controls(Loring et al., 2001; Vogelsberg-Ragaglia et al., 2001a).  
 PP2A function is also inhibited in AD through changes in regulatory proteins affecting 
PP2A activity. In Situ hybridization for I1PP2A and I2PP2A, endogenous inhibitors of PP2A 




increased co-localization of I2PP2A with PP2A and hyperphosphorylated Tau in the temporal 
cortex of AD brains, indicating that PP2A inhibition is linked with hyperphosphorylated Tau in 
disease(Tanimukai et al., 2005). The PP2A methyltransferase (PPMT) targets the catalytic subunit 
of PP2A and methylation of this subunit is required for functional holoenzyme assembly. In AD 
brains there is a decrease in PPMT protein levels and a correlated decrease in PP2A-C methylation. 
This decrease in both PPMT protein and unmethylated PP2A-C is highest in brain regions that 
show the largest increases in hyperphosphorylated Tau. The E3 ubiquitin ligase MID1 targets the 
PP2A-interacting protein α4 for ubiquitination. Monoubiquitination of α4 increases cleavage and 
the resulting fragment enhances PP2A-C degradation. Levels of cleaved α4 are significantly 
increased in AD temporal cortices, suggesting that MID1 and α4 may play a part in the mechanism 
lowering PP2A-C levels in AD and ultimately altering the phosphorylation status of Tau(Watkins 
et al., 2012a). Cancerous inhibitor of PP2A (CIP2A) is expressed at higher levels in AD patient 
brains than controls, and when cultured neurons overexpress CIP2A there is a decrease in PP2A 
activity and subsequent increase in Tau hyperphosphorylation and synapse degeneration. 
Overexpression of CIP2A in the mouse hippocampus via AAV leads to cognitive impairments as 
measured by novel object recognition and Morris water maze tasks and reductions in long term 
potentiation(Shentu et al., 2018).  
 Pharmaceutical and genetic inhibition of PP2A has been used to model aspects of AD 
pathogenesis both in vivo and in vitro. Treating primary rat hippocampal neurons with PP2A 
inhibitors OA or Calculin A reduces the number of synapses observed on dendrites, causes the 
accumulation of vesicles in the axonal compartment, and increases the levels of 
hyperphosphorylated Tau(Malchiodi-Albedi et al., 1997). Infusion of OA into the ventricles of the 




disorganization, and apoptosis(Arendt et al., 1998). Rats with calculin A injected into their 
hippocampus developed hyperphosphorylated pathology and had impaired spatial memory as 
measured by a Morris water maze(Sun et al., 2003). These pharmaceutical studies are supported 
by genetic manipulations to lower PP2A activity also increasing hyperphosphorylated Tau levels, 
including a mouse model expressing a dominant negative form of PP2A-C or genetic nulls for one 
of the B’ regulatory subunits of PP2A(Kins et al., 2001; Louis et al., 2011). Taken together, these 
studies provide evidence that PP2A inhibition is sufficient to recapitulate a portion of the 
pathology associated with AD patients, including hyperphosphorylation of Tau, the primary focus 
of many studies, as well as increased neuronal cell death, synaptic loss, behavioral deterioration, 
and memory impairment.  
1.4 Summary 
 This introduction has summarized findings about the stress kinase signaling cascade 
controlled by DLK in neurons, the role and modulation of the cytoskeleton in neurons, and the 
protein phosphatase PP2A in development and disease. I aim to address the question of whether 
there are other modulators of the cytoskeleton, in this case PP2A inhibition, which activate a DLK-
dependent transcriptional response. In this thesis I test the hypothesis that the deleterious 
downstream effects of PP2A inhibition require activation of the DLK cascade and ask whether 
blocking DLK signaling is sufficient to ameliorate these outcomes. These findings have 
implications for Alzheimer’s disease, where patients display a decrease in PP2A activity and 
hyperphosphorylation of Tau. My work demonstrates that PP2A acts to restrain DLK signaling in 
the Drosophila peripheral nervous system, inhibiting synaptic overgrowth and induction of a 
transcriptional stress response, as well as in mammalian cortical neurons where cell treated with 
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Protein phosphatase 2A (PP2A) is a major cellular phosphatase required for neuronal 
survival. PP2A activity is impaired in Alzheimer’s disease, contributing to hyperphosphorylation 
of its substrate Tau. Hyperphosphorylated Tau is toxic, and so PP2A is thought to promote 
neuronal survival via dephosphorylation of Tau. Here we identify a Tau-independent function of 
PP2A required for survival of mammalian cortical neurons. We demonstrate that PP2A inhibits 
activation of the neuronal stress kinase DLK and its Drosophila ortholog Wallenda. In the fly, 
PP2A inhibition activates a DLK/Wallenda-regulated transcriptional program that induces 
synaptic terminal overgrowth at the neuromuscular junction. In cultured mammalian neurons, 
PP2A inhibition activates a DLK-dependent apoptotic program. In the absence of Tau, PP2A 
inhibition still activates DLK and induces neuronal cell death, demonstrating that 
hyperphosphorylated Tau is not required for cell death in this model. Moreover, 
hyperphosphorylation of Tau at serine 262 following PP2A inhibition does not require DLK. 
Hence, loss of PP2A function triggers two independent neuropathologies: 1) Tau 
hyperphosphorylation and 2) DLK activation and subsequent neuronal cell death. These findings 
suggest that combination therapies targeting both Tau and DLK may be useful in 
neurodegenerative diseases with impaired PP2A function.  
2.2 Significance Statement 
Protein phosphatase 2A (PP2A) is a major cellular phosphatase required for neuronal 
survival and dephosphorylation of Tau and whose activity is decreased in Alzheimer’s disease. 
Here we demonstrate that PP2A plays an evolutionarily conserved role in flies and mice, inhibiting 
activation of MAP3K12, DLK, an important neuronal stress kinase. Inhibition of PP2A results in 




neuronal cell death in mammalian cortical neurons. Surprisingly, PP2A-dependent activation of 
DLK signaling and neuronal cell death are independent of Tau, demonstrating that Tau 
hyperphosphorylation and DLK apoptotic signaling are parallel pathways downstream of PP2A 
dysfunction. These findings identify the DLK stress kinase pathway as an important PP2A target 
in neuronal health and disease. 
2.3 Introduction  
Alzheimer’s disease (AD) is the most common form of dementia and is characterized by 
the accumulation of toxic protein species, including hyperphosphorylated Tau (Grundke-Iqbal et 
al., 1986). Protein Phosphatase 2A (PP2A) plays a central role in the dephosphorylation of Tau, 
and PP2A activity is markedly decreased in AD brains, likely contributing to the accumulation of 
hyperphosphorylated Tau (Gong et al., 1993; Liu et al., 2005; Sontag et al., 1996; Sontag and 
Sontag, 2014). Inhibiting PP2A in neurons promotes cell death both in vitro and in vivo, so the 
AD-associated decrease in PP2A activity may contribute to neuronal loss (Arendt et al., 1998; 
Kamat et al., 2013; Sun et al., 2003). Previous studies proposed that the neuronal cell death induced 
by PP2A inhibition is most likely linked to the alteration of Tau phosphorylation status (Gong et 
al., 2000a; Kins et al., 2001; Taleski and Sontag, 2018). Here, we present evidence for an 
alternative model wherein the DLK (dual leucine zipper kinase, a.k.a. MAP3K12) stress kinase 
signaling cascade is activated downstream of decreased PP2A function to promote neuronal 
apoptosis in a Tau-independent manner.  
We previously identified a role for PP2A in Drosophila synaptic development, 
demonstrating that PP2A acts antagonistically to glycogen synthases kinase 3β (GSK-3β, Shaggy 
in flies) to modulate arborization of the neuromuscular junction (NMJ). At the time, we 




dysregulation of the cytoskeleton (Viquez et al., 2009). Later, we discovered that cytoskeletal 
dysregulation activates DLK in mammals and its ortholog Wallenda (Wnd) in Drosophila (Valakh 
et al., 2013, 2015a). In flies, elevated Wnd signaling stimulates a transcriptional program that 
induces increased synaptic arborization at the Drosophila NMJ, a similar phenotype to that 
observed in flies with decreased PP2A activity (Collins et al., 2006). In mammals, increased DLK 
signaling triggers a transcriptional program that promotes axon regeneration in the peripheral 
nervous system but that can induce apoptosis in CNS neurons (Asghari Adib et al., 2018; Xiong 
et al., 2010a). Importantly, DLK signaling is increased in the brains of AD model mice and likely 
in AD patients, and inhibition of DLK extends lifespan and improves behavioral outcomes in 
mouse models of familial AD (Le Pichon et al., 2017). This confluence of findings led us to revisit 
our prior studies of PP2A, and to explore the hypothesis that PP2A inhibition may function through 
the DLK/Wnd pathway in both Drosophila and mammalian neurons.  
Here we demonstrate that loss of neuronal PP2A activity activates Wnd/DLK signaling in 
both Drosophila motor neurons and cultured mammalian cortical neurons. In the fly, increased 
Wnd signaling leads to activation of a transcriptional stress response program and resulting 
changes in synaptic morphology. Pharmacological inhibition of PP2A in mouse cortical neurons 
leads to DLK-dependent apoptosis. Surprisingly, loss of PP2A activity in Tau knockout neurons 
still activates DLK and induces apoptosis, demonstrating that the accumulation of 
hyperphosphorylated Tau and the activation of DLK apoptotic signaling are parallel pathways 
downstream of PP2A dysfunction. Hence, this study identifies PP2A as an evolutionarily 
conserved inhibitor of DLK stress kinase signaling, with potential roles in regulating both 





2.4.1 PP2A inhibits DLK signaling to restrain synaptic terminal growth at the 
Drosophila NMJ 
Neuronal PP2A function is required for restraining growth of the synaptic terminal at the 
Drosophila neuromuscular junction (NMJ) during development (Viquez et al., 2009, 2006), 
however the molecular mechanisms linking PP2A activity to proper synaptic development are 
unknown. We previously inhibited PP2A via neuronal expression of a dominant negative transgene 
(Viquez et al., 2009, 2006). We confirmed this result, through expression of the dominant negative 
(PP2A-DN) and independently verified PP2A’s role at the NMJ through expression of an RNAi 
transgene targeting the PP2A catalytic subunit, Microtubule Stars, (PP2A-C RNAi). Third instar 
larvae expressing either of these two transgenes under the control of motoneuron-specific DVGlut-
Gal4 were dissected and stained for the pre-synaptic marker Drosophila Vesicular Glutamate 
Transporter (DVGlut) to identify synaptic boutons. Each of these manipulations leads to synaptic 
overgrowth, as quantified by an increase in the number of synaptic boutons on the type 1b muscle 
4 NMJ compared to animals expressing a control transgene. While both methods to inhibit PP2A 
lead to synaptic terminal overgrowth, expression of PP2A-C RNAi also led to a decrease in signal 
while staining for synaptic antigens (Fig. 1 A and B). Neuronal expression of either of two separate 
RNAis against the related protein phosphatase PP5 induced no change in the number of synaptic 
boutons compared to expression of a control RNAi, demonstrating selectivity of the PP2A 
phenotype (Fig. 1 A and B). Having confirmed and extended our prior studies demonstrating that 
PP2A inhibition induces synaptic terminal overgrowth, we next tested the hypothesis that 





To investigate the role of Wnd/DLK signaling in the PP2A-dependent synaptic terminal 
overgrowth phenotype, we co-expressed a validated Wnd RNAi (Valakh et al., 2013) along with 
the dominant negative or an RNAi targeting the catalytic subunit of PP2A in motoneurons. 
Inhibition of Wnd/DLK leads to a significant reduction in the number of synaptic boutons at the 
NMJ, suppressing the synaptic bouton number to wildtype levels (Fig. 1 C and D). Expression of 
Wnd RNAi in a wildtype background does not affect bouton number (Fig. 1 C and D), consistent 
with the hypothesis that Wnd/DLK signaling is regulated by PP2A function. As an independent 
method of suppressing Wnd, we used an inhibitor of the mammalian ortholog DLK, GNE-3511, 
that we previously validated inhibits Drosophila Wnd (Russo and DiAntonio, 2019). 
Pharmacological inhibition of Wnd significantly reduced the number of boutons in animals 
expressing either a dominant negative PP2A or an RNAi against the catalytic subunit (Fig. 1 E and 
F). Hence, genetic and pharmacological studies demonstrate that Wnd signaling is required for the 
synaptic terminal overgrowth induced by impaired neuronal PP2A activity. 
2.4.2 A DLK-regulated transcriptional program is activated by loss of PP2A 
function   
In our original study demonstrating that decreased neuronal PP2A activity induces synaptic 
terminal overgrowth we hypothesized that this was due to local signaling converging on the 
cytoskeleton (Viquez et al., 2009). However, the known role of Wnd/DLK in regulating a 
transcriptional program to control synaptic terminal growth (Collins et al., 2006) inspired us to test 
whether there were transcriptional changes in neurons with reduced PP2A activity. We first tested 
whether inhibition of PP2A causes transcriptional changes in a well-known DLK-dependent 
cellular stress response program. To do this we employed a Puckered LacZ enhancer trap 
(PucLacZ). Expression of Puckered, a phosphatase which targets JNK, is positively regulated by 




and higher intensity of LacZ staining (Martín-Blanco et al., 1998; Xiong et al., 2010a). Expressing 
either dominant negative PP2A or RNAi targeting PP2A-C in neurons triggers a substantial 
increase in Puckered expression. Expression of RNAi lines targeting the related protein 
phosphatase PP5 did not significantly alter levels of Puckered expression (Fig. 2 A and B). These 
data demonstrate that loss of PP2A activity alters transcription in neurons and with our previous 
findings lead us to hypothesize that this transcriptional change was Wnd-dependent. Co-expression 
of Wnd RNAi with either dominant negative PP2A or PP2A-C RNAi lowered PucLacZ induction 
back to wildtype levels (Fig. 2 C and D). Therefore, we conclude that loss of neuronal PP2A 
activity results in the induction of a Wnd-dependent transcriptional response.  
We hypothesized that this Wnd-dependent transcriptional program is required for the 
synaptic overgrowth induced by loss of PP2A activity. Previously, we demonstrated that the 
transcription factor Fos is required for Wnd-dependent transcriptional changes and synaptic 
terminal overgrowth (Collins et al., 2006). Hence, we expressed a dominant negative Fos transgene 
in neurons and found it blocks the increase in number of synaptic boutons induced by PP2A 
inhibition (Fig. 2 E and F). Therefore, we conclude that loss of neuronal PP2A activity induces 
synaptic terminal overgrowth by activating a Wnd- and Fos-dependent transcriptional program. 
2.4.3 GSK-3β antagonizes PP2A upstream of DLK activation 
GSK-3β is a kinase that often functions antagonistically with the phosphatase PP2A, 
including in the regulation of synaptic terminal growth in Drosophila (Janssens and Goris, 2001; 
Viquez et al., 2009). Indeed, co-expression of a dominant negative form of GSK-3β suppresses 
both the increase in the number of synaptic boutons and the induction of the PucLacZ upon 
neuronal inhibition of PP2A (Fig. 3 A-D) (Viquez et al., 2009). Previously we postulated that 




associated proteins and thus cytoskeletal structure (Viquez et al., 2009). However, we showed 
above that the synaptic overgrowth phenotype requires a Wnd-dependent transcriptional program. 
These data present the possibility of an alternative model to that which we originally proposed, 
wherein GSK-3β may act downstream of increased Wnd signaling to effect phenotypic changes in 
animals with reduced neuronal PP2A activity. 
In order to test whether GSK-3β can act downstream of Wnd/DLK activity, we used 
highwire (hiw) mutants, an independent genotype that activates Wnd/DLK signaling and drives 
synaptic terminal growth (Collins et al., 2006). Hiw is an E3 ubiquitin ligase that targets Wnd for 
degradation, hence in hiw mutants Wnd is upregulated and activated (Collins et al., 2006). If GSK-
3β acts downstream of Wnd, then we would expect a loss of GSK-3β activity to suppress Wnd-
dependent transcriptional changes and synaptic terminal overgrowth in hiw mutants. As previously 
demonstrated, expression of both Wnd RNAi and the Fos dominant negative transgene suppress 
synaptic terminal overgrowth from loss of Hiw (Collins et al., 2006). In contrast, expression of the 
dominant negative GSK-3β that potently suppresses the PP2A phenotype fails to suppress the 
increase in synaptic bouton number when hiw is disrupted (Fig. 3 E and F). These data are not 
consistent with GSK-3β acting downstream of Wnd signaling, and instead support a model in 
which GSK-3β and PP2A antagonistically regulate a protein or process that is necessary to inhibit 
Wnd/DLK signaling.  
2.4.4 PP2A inhibition in mammalian cortical neurons induces DLK-dependent 
cell death 
Loss of PP2A activity is observed in Alzheimer’s disease patients and is thought to 
contribute to disease progression via an undefined mechanism (Shentu et al., 2018; Sontag et al., 




species of hyperphosphorylated Tau, a well-studied substrate of PP2A (Gong et al., 1993; Liu et 
al., 2005; Sontag et al., 1996). Inhibition of PP2A activity, either through genetic manipulations 
or pharmaceutical methods, in mammalian cortical neurons in vitro leads to neuronal cell death 
(Kim et al., 1999a; Kins et al., 2001). Wnd and DLK function are conserved between flies and 
mice in the axon regeneration pathway (Shin et al., 2012b; Xiong et al., 2010a). Here we 
investigate the hypothesis that PP2A-dependent inhibition of DLK signaling is also evolutionarily 
conserved, and that DLK may trigger neuronal cell death upon loss of PP2A function in 
mammalian cortical neurons.  
We first asked whether PP2A inhibition in cultured mouse cortical neurons activates DLK 
signaling. To assess DLK signaling, we assayed phosphorylation of the direct DLK substrate 
MKK4, a MAP double kinase. Primary mouse cortical neurons were cultured from E16-18 
embryos for 12 days before treatment for 4 hours with either vehicle or the selective PP2A 
inhibitor, LB-100. LB-100 treatment led to significantly higher levels of phosphorylated MKK4 
compared to those treated with a DMSO control. To test whether phosphorylation of MKK4 is 
DLK-dependent, neurons were pre-treated with either DLK inhibitor GNE-3511 or DMSO 30 
minutes before LB-100 application. Pre-treatment with DLK inhibitor blocks the increase in 
pMKK4 (Fig. 4 A and B). Hence, PP2A inhibition in mammalian cortical neurons activates DLK 
signaling. 
We next investigated whether DLK signaling promotes neuronal cell death upon PP2A 
inhibition. DLK signaling is pro-apoptotic in other contexts (Chen et al., 2008; Fernandes et al., 
2014; Ghosh et al., 2011; Pozniak et al., 2013a; Watkins et al., 2013; Welsbie et al., 2013), and so 
we first tested whether the cell death caused by PP2A inhibition is apoptotic. Primary cortical 




days. To block apoptosis, we infected cortical neurons with lentivirus expressing the anti-apoptotic 
protein BCL-XL or a control GFP construct at DIV 3. Cortical neurons were treated on DIV 9 with 
either LB-100 or DMSO and cell viability was measured using an MTT survival assay. BCL-XL-
expressing cells were significantly protected at all timepoints compared to GFP-expressing 
controls. Next, we tested whether the cell death caused by PP2A inhibition was DLK-dependent. 
Cells were treated with DLK inhibitor or DMSO 30 minutes prior to LB-100 treatment and the 
relative cell death was measured as described above. DLK inhibitor pre-treatment phenocopied 
BCL-XL expression, potently protecting neurons treated with LB-100 out to 72 hours after 
treatment (Fig. 4C). These findings demonstrate that PP2A inhibition in cultured cortical neurons 
leads to a cell death that is both apoptotic and DLK-dependent.   
2.4.5 PP2A inhibition Triggers DLK-dependent Neuronal Cell Death 
Independent of Tau  
The microtubule-associated protein Tau is a well-defined target of PP2A. Loss of PP2A 
activity leads to an alteration in the phosphorylation pattern of Tau, which can form a toxic protein 
species that is a hallmark of Alzheimer’s disease and tauopathies. We investigated whether 
hyperphosphorylated Tau participates in DLK-dependent cell death following PP2A inhibition. 
We first asked whether DLK signaling influences Tau phosphorylation at serine 262, a known 
target of PP2A and a site of increased phosphorylation in neurodegenerative diseases (Keramidis 
et al., 2020; Liu et al., 2005; Qian et al., 2010). Primary mouse cortical neurons expressed either 
BCL-XL or a GFP control or were treated with either DMSO or DLK inhibitor 30 minutes prior 
to treatment with LB-100. Following 4 hours of LB-100 treatment, protein was collected and levels 
of Tau phosphorylated at serine 262 (pTau) was measured by Western blot. PP2A inhibition led 




blocked this effect (Fig. 5 A and B). Hence, levels of Tau phosphorylated at serine 262 are not 
changed by conditions that block neuronal cell death following PP2A inhibition.  
Having demonstrated that DLK signaling is not required for increased phosphorylation of 
Tau at serine 262, we next asked the converse question—is hyperphosphorylated Tau necessary to 
activate DLK signaling following PP2A inhibition? This is an attractive hypothesis because we 
previously demonstrated that disrupting the mammalian cytoskeleton can activate neuronal DLK 
signaling (Valakh et al., 2013, 2015a), and a dysregulated cytoskeleton is observed in cases of 
increased Tau phosphorylation (Merrick et al., 1997; Sontag et al., 1999). We cultured neurons 
from Tau knock out mice, treated them with LB-100, and assessed DLK activation by measuring 
levels of phosphorylated MKK4. Results from Tau knockout and wildtype neurons were very 
similar, showing an increase in pMKK4 four hours after treatment with LB-100 (Fig. 5 C and D). 
These results demonstrate that hyperphosphorylated Tau is not required for the activation of DLK 
signaling following PP2A inhibition.  
The findings above lead us to hypothesize that cell death triggered by PP2A inhibition is 
DLK-dependent and Tau-independent. To test this, we treated neurons cultured from Tau KO mice 
with LB-100 and measured cell death, predicting that the neurons would die even in the absence 
of hyperphosphorylated Tau. Tau KO neurons showed significant cell death 72 hours after LB-
100 treatment, phenocopying results observed in wildtype neurons and demonstrating that Tau is 
not necessary for PP2A inhibition to trigger cell death (Fig. 5 E and F). Hence, PP2A inhibition 
activates two independent pro-degenerative pathways, DLK activation and Tau 
hyperphosphorylation. Targeting both DLK and Tau may offer benefits for the treatment of 





Here we demonstrate that PP2A acts to inhibit DLK signaling in neurons. Our study, in 
conjunction with prior work, supports a model wherein PP2A inhibition alters the cytoskeleton 
which triggers an increase in DLK signaling. Activated DLK induces a transcriptional stress 
response that alters synaptic development at the Drosophila NMJ and promotes cell death in 
mammalian cortical neurons. Moreover, we show that PP2A-dependent inhibition of DLK-
induced neuronal cell death and Tau hyperphosphorylation are independent. These findings 
identify a mechanistic link between PP2A inhibition and DLK activation with implications for the 
pathogenesis of neurodegenerative diseases.  
2.5.1 PP2A and DLK/Wallenda signaling 
PP2A and GSK-3β function antagonistically in neurons to regulate the status of a family 
of substrates including many microtubule-associated proteins, ultimately affecting the 
organization of the cytoskeleton (Janssens and Goris, 2001). Our previous studies demonstrated 
that this pair acts to control synaptic terminal morphology at the Drosophila NMJ, and we assumed 
at the time this was due to local disruption of the cytoskeleton (Viquez et al., 2009). However, here 
we have shown that PP2A and GSK-3β collaborate to inhibit the activation of a downstream MAP 
kinase signaling cascade headed by the MAP triple kinase DLK/Wallenda. DLK is a major 
neuronal stress kinase that is activated by cytoskeletal disruption in both Drosophila and mammals 
(Asghari Adib et al., 2018; Valakh et al., 2013, 2015a), suggesting that DLK acts as a sensor and/or 
effector downstream of cytoskeletal perturbations in neurites. While Wnd/DLK can function 
locally at the NMJ (Klinedinst et al., 2013), in cases of injury, the DLK/JNK signaling module is 
transported retrogradely to the nucleus, where it activates a transcriptional response to mount a 




disparate responses depending on the context of activation, such as neuronal subtype, including a 
regenerative process that triggers increased growth at the Drosophila NMJ and the injured 
mammalian PNS (Hammarlund et al., 2009b; Shin et al., 2012a; Xiong et al., 2010a; Yan et al., 
2009), but induces a pro-apoptotic signal in mammalian retinal ganglion cells and cortical neurons 
(Chen et al., 2008; Pozniak et al., 2013a; Watkins et al., 2013; Welsbie et al., 2013). Here, we 
propose a model to tie these findings together, suggesting that PP2A acts to maintain cytoskeletal 
homeostasis that in turn keeps DLK signaling at a low basal state. When PP2A activity is disrupted, 
the cytoskeleton is perturbed and DLK is activated, triggering the stress response appropriate for 
that cell, including death of cortical neurons. Hence, a subset of the deleterious outcomes attributed 
to inhibition of neuronal PP2A is due to the secondary activation of DLK. 
2.5.2 PP2A signaling, Tau, and the mechanism of neuronal cell death  
PP2A inhibition causes cell death both in vitro and in vivo indicating that PP2A function 
is essential for neuron survival in the central nervous system (Kamat et al., 2013; Kim et al., 1999b; 
Kins et al., 2001). Loss of PP2A function is observed in Alzheimer’s disease patient brains, due to 
lowered mRNA levels of the PP2A catalytic subunit, increased expression of the inhibitor protein 
cancerous inhibitor of PP2A (CIP2A), and changes in expression of methyltransferases that 
regulate PP2A activity (Gong et al., 1993, 1995; Liu et al., 2005; Park et al., 2018; Shentu et al., 
2018; Sontag et al., 2004; Vogelsberg-Ragaglia et al., 2001a). Taken together, the strong evidence 
that PP2A activity is lowered in patient brains has motivated mechanistic studies of the role of 
PP2A in neuronal survival. One of the best studied targets of PP2A in the nervous system is Tau, 
which forms toxic species when hyperphosphorylated that are present not only in Alzheimer’s 
disease patient brains but also in tauopathies (Gong et al., 1995; Liu et al., 2005; Merrick et al., 




Tau hyperphosphorylation and neuronal cell death has led to the hypothesis that this neuronal cell 
death is due to the effects of hyperphosphorylated Tau (Iqbal et al., 2009; Taleski and Sontag, 
2018). Here we test this model directly by assessing the impact of PP2A inhibition in the absence 
of Tau and explore alternate mechanisms for this neuronal cell death.  
 We find that PP2A inhibition activates a DLK signaling cascade that promotes cortical 
neuron cell death. The MAP triple kinase DLK is a major neuronal stress kinase, sensing cellular 
stress and launching a transcriptional program in response (Asghari Adib et al., 2018; Valakh et 
al., 2015a; Xiong et al., 2010a). Increased DLK signaling is implicated in neurodegenerative 
diseases—signaling is elevated in murine models of Alzheimer’s disease and amyotrophic lateral 
sclerosis (ALS) and DLK inhibition improved neuronal survival and behavioral phenotypes in 
these models. Moreover, increased levels of a key target of DLK signaling, the phosphorylated 
form of the transcription factor Jun, is observed in post-mortem nervous tissue of Alzheimer’s and 
ALS disease patients (Le Pichon et al., 2017). Together, our findings and published work support 
the hypothesis that inappropriate activation of DLK is common to multiple neurodegenerative 
diseases, and that dampening this stress pathway has potential as a treatment.  
 Finally, we explored potential mechanistic links between the Tau hyperphosphorylation 
and increased DLK signaling that occur as a consequence of PP2A inhibition. Surprisingly, we 
find that when PP2A is inhibited, hyperphosphorylation of Tau is not required for either DLK 
activation or neuronal death. This exciting result extends our understanding of neurodegenerative 
mechanisms downstream of PP2A inhibition. In patients, we expect that both hyperphosphorylated 
Tau and activated DLK will contribute to neuropathology, suggesting that therapies targeting both 





2.6 Material and Methods 
Fly Stocks and Husbandry. Drosophila were maintained using standard techniques and raised at 
25°C and 60% relative humidity. The following stocks were used in this study: HiwND9 (Wan et 
al., 2000), DVGlut-gal4 (Daniels et al., 2008), UAS-PP2A-DN, a dominant negative form of PP2A 
catalytic subunit microtubule stars obtained from Suzanne Eaton (Hannus et al., 2002), Wallenda 
RNAi (Vienna stock center, #103410), PucLacZE69(Martín-Blanco et al., 1998), elav-gal4 (Yao 
and White, 1994). Fly stocks obtained from the Bloomington Stock Center included: UAS-PP2A-
C RNAi, an RNAi targeting the catalytic subunit of PP2A microtubule stars (#27723), UAS-
sggA81T, a dominant negative form of the Drosophila ortholog of GSK-3β (#5359), UAS-LexA 
RNAi (#67947), UAS-PP5 RNAi (#42794 and #57307), UAS-Fos-DN (#7214). Gal4 drivers were 
crossed to UAS-LexA RNAi as a control for expression of experimental constructs. Roughly equal 
numbers of male and female flies were tested, with the exception of Hiw mutants and crosses using 
the DVGlut-gal4 driver, in which cases only males were examined. Flies raised on DLK inhibitor 
were crossed in vials with 35 µM GNE-3511 (MedChem Express HY-12947) or an equivalent 
volume of DMSO in Instant Drosophila Blue Food Medium (Carolina, #173210) (Russo and 
DiAntonio, 2019).  
Immunohistochemistry. Wandering third instar larvae were dissected in cold PBS and fixed in 
either bouin’s fixative for 10 minutes (DVGlut, HRP) or 4% PFA in PBS for 20 minutes (Elav, 
beta-galactosidase). After fixing, larvae were washed in PBS + 0.1% Triton X-100 (PBS-T) 
followed by blocking in 5% normal goat serum in PBS-T for at least 30 minutes. All antibodies 
were incubated in 5% normal goat serum blocking solution. The following antibodies were used: 
rabbit anti-DVGlut (1:5,000 (Daniels et al., 2004)), rat anti-Elav (1:50, Developmental Studies 




Hybridoma Bank AB_2314509). The following secondary antibodies were used at 1:1000 for 90 
minutes: cy3-conjugated goat anti-HRP (Jackson ImmunoResearch, Cat# 123-165-021; 
AB_2338959), AlexaFluor 488 goat anti-rabbit (ThermoScientific – Invitrogen, Cat# A-11034; 
AB_2576217), cy3 goat anti-mouse (Jackson ImmunoResearch, Cat# 115-165-146; 
AB_2338680), and AlexaFluor 488 chicken anti-rat (ThermoScientific – Invitrogen Cat# A-
21470; AB_2535873). After secondary staining, larval preps were stored in 70% glycerol in PBS 
until being mounted in vectashield (Vector Laboratories).  
Imaging and Image Analysis in Drosophila. Synaptic growth was assessed using larval preps 
stained for DVGlut and HRP which were imaged using the 40X objective on a Leica TCS SPE 
confocal microscope. Images shown were all taken at the same gain, adjusted to be as bright as 
possible without oversaturation, and with identical z-stack step sizes. Bouton number was 
quantified as previously described (Collins et al., 2006). DVGlut-positive boutons were manually 
counted on muscle 4 of larval segments A2-A4. PucLacZ measurements were taken by staining 
larval ventral nerve cords and taking images with a Leica TCS SPE confocal microscope using the 
20X objective. Average PucLacZ intensity was quantified in the neuronal nuclei along the dorsal 
midline of the ventral nerve cord as described previously (Xiong et al., 2010a). Briefly, neurons in 
the z-stack images are identified using an Elav stain and the average intensity of beta-galactosidase 
is measured in the defined area. All images were taken at the same gain and with the same z-step 
size for all conditions in each experiment. 
Primary Cortical Neuron Culture. Primary neurons were cultured from E16.5-E18.5 mouse 
embryos. For Fig.ure 4 CD1 mice were used, and for Fig.ure 5 C57BL/6 mice (Charles River 
Laboratories) were used as wildtype controls for Tau KO mice obtained from John Cirrito 




Solution and digested in Accumax (StemCell Technologies, cat# 07921) for 25 minutes. Digested 
cells were then rinsed once in neurobasal media with 10% fetal bovine serum, followed by 
trituration of the cell pellet in this media and plating at 250,000 cells per mL. Four hours after 
plating, media was changed to maintenance media of neurobasal media with 1:50 B-27 supplement 
(Thermo Fischer Scientific, cat# 17504044). Half of media was changed every 3 days and included 
a 1:200 addition of FDU to prevent growth of non-neuronal cells. On DIV 3 lentivirus was added, 
either a GFP control or a BCL-XL construct. Cells were treated with 1 µM LB-100 on DIV 9 or 
an equivalent volume of DMSO then treated 24 hours later for cell survival studies or collected 4 
hours later for Western blotting assays. Cells treated with DLK inhibitor were treated 30 minutes 
prior to LB-100 treatment with 500 nM GNE-3511 (MedChem Express HY-12947) or an 
equivalent volume of DMSO.  
Western Blots. To analyze phosphorylation evens on Tau and MKK4 following LB-100 treatment 
protein was collected and analyzed by Western blot from DIV 10 primary cortical neurons. Protein 
was collected in RIPA buffer with protease inhibitor (Millipore Sigma, cat# 11873580001) and 
phosphatase inhibitor (Sigma-Aldrich, cat# P0044) after washing cells in ice cold PBS. Cells were 
spun down for 4 minutes at 4,000 RCF, then protein was mixed with Laemmli buffer and 2-
mercaptoethanol (Sigma-Aldrich, cat# M3148) and boiled at 100°C for 10 minutes. Samples were 
run on 4-20% Mini-PROTEAN® TGX Precast Protein Gels (Bio-Rad Laboratories, cat# 4561093) 
in duplicate, with one gel being reserved for the phosphorylated form of the protein and the other 
for the non-phosphorylated control. Gels were transferred to nitrocellulose membranes using 
Trans-Blot® Turbo Midi Nitrocellulose Transfer Packs (Bio-Rad Laboratories, cat# 1704159). 
Membranes were blocked in 5% bovine serum albumin (Sigma-Aldrich, cat# A3912-50G) in 




antibodies overnight: 1:1,000 rabbit anti-MKK4 (Cell Signaling Technologies, cat# 9152), 1:1,000 
rabbit anti-phospho-MKK4 (ser257/thr261) (Cell Signaling Technologies, cat# 9156), 1:500 
mouse anti-Tau-5 (Thermo Fischer Scientific, cat# MA512808), 1:200 rabbit anti-phospho-Tau 
(ser262) (Thermo Fischer Scientific, cat# 44750G), 1:5,000 rabbit anti-HSP90 (Cell Signaling 
Technologies, cat# 4877S). Membranes were then incubated in the following secondary antibodies 
in PBST + 5% BSA for 60 minutes: Peroxidase AffiniPure Goat Anti-Rabbit IgG (Jackson 
ImmunoResearch Laboratories cat# 111-035-045) at 1:5,000 for MKK4, pMKK4, and Tau-5 blots 
and 1:10,000 for HSP90 blots, Peroxidase AffiniPure Goat Anti-Mouse IgG (Jackson 
ImmunoResearch Laboratories, cat# 115-035-003) at 1:5,000. Western blots were developed with 
Immobilon Western Chemiluminescent Substrate (EMD Millipore) and imaged on a G:Box 
Chemi-XX6 (Syngene). Blots were quantified using ImageJ (NIH, v1.53c), with phosphorylated 
forms of proteins being normalized to the non-phosphorylated forms.  
MTT Assay. Cortical neurons were cultured as described above in 96 well plates. On DIV 9, 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Thermo Fischer Scientific, 
cat# M6494) was dissolved in sterile PBS at 5mg/mL. An appropriate volume was added to media 
such that changing half of the media in the 96 well plate resulted in a final concentration of 
0.5mg/mL. Cells were incubated with MTT for 4 hours then lysed by replacing media with DMSO 
(50 µL per well). The active cells converted MTT into formazan, resulting in a purple solution the 
intensity of which was measured using the absorbance setting on a POLARstar OPTIMA plate 
reader (BMG LabTech). Background was subtracted from all cells based on the average reading 
of 8 wells without cells. Percent of cell death was calculated by comparing individual well readings 




Experimental Design and Statistical Analyses. For quantification of synaptic boutons at the 
neuromuscular junction at least 3 larvae were quantified for each genotype with each NMJ being 
an N of 1, as each motor neuron targets a single muscle 4 hemi-segment. For the quantification of 
PucLacZ intensity in the ventral nerve cord at least 2 larvae were used per genotype, with each 
larva representing an N of 1. Experimental genotypes were compared to control genotypes on the 
same slide and from the same dissection, with all measurements being performed blinded to the 
genotype. Western blot experiments were run at least 3 times with each experiment being a 
separate biological replicate, ie: collected neurons were from different mice. Protein collected was 
pooled from 2-3 technical replicates (wells on the same plate). MTT assays were repeated with at 
least 3 biological replicates and at least 4 technical replicates (wells on the same plate).  
All data is represented as mean ± SEM with exact values represented as individual data points 
where possible. Statistical tests are described below each Fig.ure, including p-value. GraphPad 
Prism 9 was used to perform all statistical tests. 
2.7 Acknowledgements 
This work was funded by NIH R37 NS065053 awarded to A.D. We thank John Cirrito for the Tau 
knockout mice used in these experiments. We are also grateful to all members of the DiAntonio 










Figure 1. PP2A inhibits DLK signaling to restrain synaptic terminal growth at the Drosophila NMJ  
(A) Representative images of synaptic terminal overgrowth at the NMJ of third instar larvae. Transgenes 
are being driven by DVGlutgal4 in the presence of UAS-Dcr to improve RNAi knockdown. Tissue is 
stained for the presynaptic marker DVGlut (green) and the nerve membrane with anti-HRP (red). Scale bar 
is 25 µM. (B) Quantification of the mean (± SEM) number of boutons on the type 1b synapse on muscle 4. 
Expression of PP2A-DN or PP2A-C RNAi significantly increases the number of boutons compared to an 




        
         
        
       
           
          
          
 
  
   

















    
   
 
  
   



















   

















        
           
                 
                                      
                                  
        
                      
              
              
                  
        
                




comparison test. Expression of either of two RNAis against PP5 is not significantly different from animals 
expressing a control RNAi (p = 0.8450 and p = 0.9991 respectively). (C) Representative images of the 
suppression of synaptic terminal overgrowth from PP2A inhibition by Wnd RNAi in third instar larvae. 
Transgenes are being driven by DVGlutgal4 in the presence of UAS-Dcr to improve RNAi knockdown. 
Tissue is stained for the presynaptic marker DVGlut (green) and the nerve membrane with anti-HRP (red). 
Scale bar is 25 µM. (D) Quantification of the mean (± SEM) number of boutons in larvae driving constructs 
using DVGlutgal4 and UAS-Dcr. Co-expression of Wnd RNAi compared to co-expression a LexA RNAi 
control with PP2A inhibition significantly suppresses an increase in synaptic bouton number (p < 0.0001 
for PP2A-DN and p = 0.0004 for PP2A-C RNAi). Statistical significance was measured by a one-way 
ANOVA with Tukey’s multiple comparison test. (E) Representative images of the suppression of synaptic 
terminal overgrowth in third instar larvae from PP2A inhibition by DLK inhibitor (GNE-3511, 35 µM). 
Transgenes are being driven by DVGlutgal4 in the presence of UAS-Dcr to improve RNAi knockdown. 
Tissue is stained for the presynaptic marker DVGlut (green) and the nerve membrane with anti-HRP (red). 
Scale bar is 25 µM. (F) Quantification of the mean (± SEM) number of boutons in larvae fed either DMSO 
or DLK inhibitor (GNE-3511, 35 µM). Being raised on DLKi as compared to DMSO significantly 
suppressed synaptic overgrowth in larvae expressing Hiw RNAi (p < 0.0001), PP2A-DN (p <0.0001), or 
PP2A-C RNAi (p =0.0003) under a DVGlutgal4 with UAS-Dcr. Statistical analysis was done using 

































Figure 2. A DLK-regulated transcriptional program is activated by loss of PP2A function 
(A) Representative images of ventral nerve cords in larvae expressing neuronal transgenes to inhibit 
neuronal PP2A or PP5. The neuronal protein Elav is stained in green and LacZ from the PucLacZ 
enhancer trap is stained in red. Transgenes are expressed using the pan-neuronal driver ElavGal4 along 
with UAS-Dcr to improve RNAi knock down. Scale bars are 50 µM. (B) Quantification of the mean (± 
SEM) PucLacZ fold induction in neurons of the ventral nerve cord. Expression of PP2A-DN or PP2A-C 
RNAi (p <0.0001 for both) significantly increases PucLacZ induction compared to expression of a control 
LexA RNAi, but PP5 RNAi expression has no significant effect (p =0.8506 for PP5 RNAi #1 and p 
=0.395 for PP5 RNAi #2) from a one-way ANOVA analysis with Tukey’s multiple comparison test. (C) 
Representative images of the ventral nerve cords in larvae expressing transgenes under the neuronal 






































   

















         
           
       
          
          





























        
         
    
                 
                     
                    
                
       
         
                 
                                    
                     
        
    
    




is stained in red. Transgenes are expressed using the pan-neuronal driver ElavGal4 along with UAS-Dcr 
to improve RNAi knock down. Scale bars are 50 µM. (D) Quantification of the mean (± SEM) PucLacZ 
fold induction in neurons of the ventral nerve cord. Expression of Wnd RNAi with PP2A-DN (p =0.0002) 
or PP2A-C RNAi (p =0.0002) significantly suppresses PucLacZ induction compared to co-expression 
with a control LexA RNAi. Statistical significance was measured by one-way ANOVA with Tukey’s 
multiple comparison test. (E) Representative images of neuromuscular junctions on muscle 4 of third 
instar larvae. Tissue is stained for presynaptic marker DVGlut (green) and neuronal membrane marker 
HRP (red). Expression of transgenes is driven by the glutamatergic neuron driver DVGlutgal4 in the 
presence of UAS-Dcr to improve RNAi processing. Scale bars are 25 µM. (F) Quantification of the mean 
(± SEM) number of boutons on muscle 4. Driving Fos-DN suppresses an increase in synaptic bouton 
number when co-expressed with PP2A-DN or PP2A-C RNAi compared to co-expression of a control 
LexA RNAi (p <0.0001 for both forms of PP2A inhibition). Statistical significance was measured by one-









































Figure 3. GSK-3β counteracts PP2A upstream of DLK activation 
(A) Representative images of neuromuscular junction of muscle 4 of third instar larvae. Larvae are 
expressing either PP2A-DN or PP2A-C RNAi under the DVGlutgal4 driver with UAS-Dcr to inhibit 
PP2A function along with either a control RNAi against LexA or a GSK-3β-DN transgene. Tissue is 
stained for the presynaptic marker DVGlut (green) and the nerve membrane with anti-HRP (red). Scale 
bars are 25 µM. (B) Quantification of the mean (± SEM) number of synaptic boutons. Co-expression of 
GSK-3β-DN with PP2A-DN or PP2A-C RNAi compared to co-expression of a control LexA RNAi 
significantly suppresses the number of synaptic boutons (p <0.0001 for both). Transgenes are driven by 
DVGlutgal4 and express UAS-Dcr to improve RNAi knockdown. Statistical analysis comes from a one-






   















































    
 
  
   
   
















      
         
                                      
                                     
                 
         
    
       
         
              
         
        
       
        




                




the ventral nerve cord of larvae expressing a control RNAi, PP2A-DN, or PP2A-DN in conjunction with 
GSK-3β-DN. The neuronal protein Elav is stained in green and LacZ from the PucLacZ enhancer trap is 
stained in red. Transgenes are expressed using the pan-neuronal driver ElavGal4. Scale bars are 50 µM. 
(D) Quantification of the mean (± SEM) fold change of PucLacZ induction in neurons of the ventral 
nerve cord. Co-expression of GSK-3β-DN with PP2A-DN significantly suppresses the increased PucLacZ 
induction (p <0.0001). Transgenes are driven by the neuronal driver ElavGal4 and a one-way ANOVA 
with Tukey’s multiple comparison test was performed. (E) Representative images of neuromuscular 
junctions on muscle 4 of third instar larvae. Tissue is stained for the presynaptic marker DVGlut (green) 
and the nerve membrane with anti-HRP (red). Highwire mutants (HiwND9) express transgenes under the 
neuronal driver ElavGal4 with UAS-Dcr to improve RNAi knockdown. Transgenes include a control 
RNAi, Wnd RNAi, Fos-DN, and GSK-3β-DN. Scale bars are 25 µM. (F) Quantification of the mean (± 
SEM) number of synaptic boutons. Synaptic overgrowth in HiwND9 is suppressed by neuronal expression 
of Wnd RNAi or Fos-DN (p <0.0001 for both), but not by expression of GSK-3β-DN (p =0.7608) with 
the ElavGal4 driver and UAS-Dcr to improve RNAi knockdown. Statistical analysis was performed with 









































Figure 4. PP2A inhibition in mammalian cortical neurons induces DLK-dependent cell death 
(A) Quantification of the mean (± SEM) of pMKK4 in mouse cortical neurons after 4 hours of LB-100 
treatment. pMKK4 significantly increases following LB-100 treatment (p =0.0005) while treating the 
cells 30 minutes before LB-100 with 500 nM blocks this increase (p =0.9476). Statistical analysis was 
performed with a ratio paired T-test. 
(B) Representative western blots stained for pMKK4 (serine 257/threonine 261) and HSP90 on one blot 
and MKK4 and HSP90 on a second blot. Primary mouse cortical neurons were treated with 1 µM LB-100 
on DIV 12 after being pre-treated by 30 minutes with either DMSO or 500 nM DLKi.  
(C) Quantification of the mean (± SEM) relative amount of living cells as measured by MTT assay. 
Biological replicates were normalized to the level of living cells after 0 hours of 1 µM LB-100 treatment 
for 24 hours, 48 hours, and 72 hours following treatment. Cells were expressing a GFP control or the anti-
apoptotic protein BCLXL or were pre-treated for 30 minutes before LB-100 treatment with either DMSO 
or 500 nM DLKi. Each data point represents a biological replicate which is the average of at least 4 
technical replicates. There are significantly more living cells in the BCLXL group compared to the GFP-
expressing control group at 24, 48, and 72 hours after LB-100 treatment (p =0.000041, p <0.000001, p 
  
 
        
         
             
             
            
             























                   





   
   









                 




<0.000001 respectively). There are significantly more living cells in the DLKi-treated group compared to 
the DMSO-treated group at 24, 48, and 72 hours after LB-100 treatment (p = 0.000054, p <0.000001, p 
<0.000001 respectively). There is no significant difference in the percentage of living cells between the 
BCLXL-expressing group and the DLKi-treated group at 24, 48, or 72 hours following LB-100 treatment 














































Figure 5. PP2A inhibition triggers DLK-dependent neuronal cell death independent of Tau 
(A) Representative western blots stained with pTau (serine 262), total Tau (Tau-5), and HSP90. Primary 
mouse cortical neurons were treated with 1 µM LB-100 for 4 hours. Cells were expressing either a GFP 
control or BCLXL or were treated 30 minutes before LB-100 treatment with either DMSO or 500 nM 
DLKi. (B) Quantification of the mean (± SEM) fold change in pTau (serine 262) levels following 4 hours 
of exposure to 1 µM LB-100 in primary mouse cortical neurons. Cells were expressing a GFP control or 
the anti-apoptotic protein BCLXL or were pre-treated 30 minutes before the addition of LB-100 with 
DMSO or 500 nM DLKi. There is no significant difference found between any of the treatment groups by 
a one-way ANOVA with Tukey’s multiple comparison test. (C) Representative western blots showing 
pMKK4 (serine 257/threonine 261), MKK4, and HSP90 levels in primary cortical neurons from wildtype 
(C57BL/6) or Tau KO mice treated with 1 µM LB-100 for 4 hours. Cells were pre-treated 30 minutes 
before the addition of LB-100 with either DMSO or 500 nM DLKi. (D) Quantification of the mean (± 
SEM) fold change in pMKK4 following LB-100 treatment in primary cortical neurons from wildtype 
(C57BL/6) and Tau KO mice pre-treated with DMSO or 500 nM DLKi. Both wildtype and Tau KO mice 


































              
                 
         
              
     
   
     
        
     
         
    
     
    
     
              
        





























   









              




the presence of Tau (p =0.6242). Statistical significance was measured by two-way ANOVA. (E) 
Quantification of mean (± SEM) relative amount of living cells as measured by an MTT assay in primary 
cortical neurons from wildtype and Tau KO mice following treatment with 1 µM LB-100 for 0, 24, 48, 
and 72 hours. Each data point represents a biological replicate which is the average of at least 4 technical 
replicates. There is no significant difference in the percentage of living cells at 24, 48, or 72 hours after 
LB-100 treatment between wildtype and Tau KO neurons (p = 0.214032, p = 0.784189, and p = 0.803735 





Chapter 3: Discussion and Future Directions 
My work here demonstrates a DLK-dependent program downstream of PP2A inhibition in 
vivo in the developing Drosophila peripheral nervous system and in vitro in the mammalian central 
nervous system. In the fly nervous system PP2A inhibition had been previously demonstrated to 
cause synaptic overgrowth but was hypothesized to be caused by a loss of cytoskeletal support. In 
this work, I have instead shown that this altered synaptic structure is dependent on a DLK-headed 
transcriptional program. I further demonstrated that the neurotoxicity of pharmacological PP2A 
inhibition in cultured mammalian cortical neurons is also a DLK-dependent process. Indeed, the 
increase in Tau phosphorylation is independent from the cell death and from DLK signaling. 
Together, these findings provide insight into a disease-relevant process and provide evidence for 
DLK as a therapeutic target.  
3.1 DLK and the cytoskeleton  
Loss of PP2A function has been well-documented to cause cytoskeletal dysregulation 
through multiple mechanisms. DLK signaling has been demonstrated to be activated by alteration 
to cytoskeletal structure or function in specified contexts, including here with PP2A inhibition. 
However, it remains unclear what about cytoskeletal dysregulation is activating DLK signaling. 
Further, does increased DLK signaling affect cytoskeletal structure and function? Are we able to 
identify a subset of genes regulated by the transcriptional program that affect the cytoskeleton and 
are they sufficient to suppress synaptic overgrowth or cell death phenotypes? 
 Neuronal insults where the cytoskeleton is dysregulated converge on DLK stress signaling, 
but these have not been shown to require cytoskeleton dysregulation to activate DLK(Valakh et 
al., 2015b, 2013, 2012). PP2A acts on several substrates and signal transduction mechanisms, so 




through another mechanism. To test this, one could attempt to stabilize the cytoskeleton while 
inhibiting PP2A. This could be done genetically in the Drosophila system or pharmacologically 
with cortical neurons. Overexpression of the spectraplakin Short Stop or the neuronal MAP Futsch 
provide excellent candidates to stabilize the cytoskeleton(Roos et al., 2000; Valakh et al., 2013). 
Short Stop is particularly attractive as it affects both microtubules and actin, and it remains unclear 
if one aspect of the cytoskeleton more strongly affects DLK activation. The actin stabilizing drug 
Jasplakinolide was sufficient to restore the membrane-associated periodic structure, a cytoskeletal 
arrangement of microtubules and actin in the axon, following neurotrophic depletion and reduced 
the DLK-dependent p-Jun induction in this model(Wang et al., 2019). Thus, this treatment seems 
a likely candidate to stabilize the cytoskeleton when PP2A is inhibited and test whether levels of 
p-MKK4, a readout of DLK activation, drop when cells are co-treated with PP2A inhibitor and 
Jasplakinolide. If either of these systems work to reduce DLK signaling in the presence of PP2A 
inhibition, follow up studies will have to be done to confirm a stabilization of the cytoskeleton and 
test whether the membrane-associated periodic structure is affected by PP2A inhibition and intact 
following stabilizing treatment. 
 The neuronal cytoskeleton is well-defined as being disrupted following PP2A inhibition 
and I have demonstrated here that some of the downstream effects of PP2A inhibition are DLK-
dependent. However, I have not yet tested whether loss of DLK signaling reduces cytoskeletal 
dysregulation. As a first step to explore this one could use the previously employed quantitative 
measures of cytoskeletal stability, such as EB1-GFP comets, to test for whether DLK inhibition 
affects cytoskeletal stability in neurons with lowered PP2A activity compared to those with intact 
DLK signaling. The proposed experiments would test the hypothesis that DLK signaling, being 




cytoskeleton. If this hypothesis was supported one would expect that neurons with PP2A inhibited 
but DLK signaling intact would display some level of increased cytoskeletal stability compared to 
neurons with both PP2A and DLK inhibited. Alternatively, it is also plausible that loss of DLK 
signaling will increase cytoskeletal stability as the downstream phenotypes of PP2A inhibition, 
such as synaptic overgrowth at the Drosophila NMJ, were previously posited to be caused by a 
lack of cytoskeletal support and I have shown here that a reduction in DLK signaling suppresses 
these phenotypes(Viquez et al., 2009). Thus, one would predict that neurons with PP2A and DLK 
both inhibited have a more stable cytoskeleton than those with increased DLK signaling.  
 Lastly, it remains unclear exactly which genes in the DLK-controlled transcriptional 
program are required for the observed phenotypes following PP2A inhibition. Our lab has 
performed a microarray screen for genes that are upregulated following sciatic nerve injury in 
mice, but whose induction is blocked in DLK knockout animals(Shin et al., 2019). The resulting 
genes are defined as being part of a DLK-dependent transcriptional program. While these two 
insults, sciatic nerve crush and PP2A inhibition, are distinct, the genes defined in this study provide 
a probable first set of genes to test. If DLK-dependent phenotypes from PP2A inhibition are the 
result of a single gene that would be relatively simple to test for suppression. However, it seems 
likely that several genes involved in cellular processes will be alternatively regulated following 
PP2A inhibition. Hence, it may be more prudent to start testing whether the same genes are 
differentially regulated following PP2A inhibition as in sciatic nerve crush and following up on 
any differences between the two paradigms.  
3.2 PP2A modulation 
In these studies, I have inhibited PP2A using the catalytic subunit. This inhibits all PP2A 




subunits(Janssens and Goris, 2001). Is there a specificity to which forms of PP2A are required for 
restraining DLK signaling? PP2A function was also only inhibited directly in these studies, but 
this is a tightly regulated protein. Do the same proteins modulating PP2A activity in AD patients 
and disease models inhibit PP2A such that the downstream phenotypes are DLK-dependent? 
 Expression and incorporation of PP2A A and B regulatory subunits varies drastically 
depending on cell type, point in development, and even cellular localization(Janssens and Goris, 
2001). Because I have inhibited the catalytic subunit of PP2A in all experiments, either genetically 
in Drosophila or pharmacologically in mammalian neurons, I cannot say whether a specific 
subunit of PP2A is involved in reducing DLK signaling. The simplest way one could test whether 
loss of a single regulatory subunit is sufficient to lose control of DLK signaling would be to screen 
knockdown of regulatory subunits in Drosophila neurons for synaptic overgrowth or PucLacZ 
induction. If any were found one could then test whether genetic knockdown in cortical neurons 
also affected DLK activation. It is possible that these two cell types would have different regulatory 
subunits modulating phenotypes, but flies present an ideal system for a small genetic screen. Any 
insight into differences between which PP2A subunits are required for DLK restraint in peripheral 
nervous system versus central nervous system would also provide a basis for further investigation 
into any differences in DLK activation triggers between cell types. Loss of the B’ subunit well-
rounded in Drosophila causes a decrease in synaptic boutons(Viquez et al., 2006). Previously, 
activation of DLK/Wnd signaling has only been observed to increase synaptic bouton number, but 
the fact that there is a change in synaptic morphology in these animals warrants testing whether 
DLK signaling is affected. B’ subunit PR61 knockout mice have increased levels of 




these studies support the hypothesis that specific PP2A regulatory subunits are involved 
downstream phenotypes. 
 It also remains unclear whether inhibition of all PP2A activity is required for DLK 
activation, or whether a more nuanced regulation of signaling is sufficient. In AD patient brains 
total levels of PP2A-C protein and expression are lowered, but there are also changes to other 
proteins regulating PP2A(E et al., 2004; Sontag and Sontag, 2014; Vogelsberg-Ragaglia et al., 
2001b). Understanding if inhibition of PP2A through these changes in regulatory proteins also 
activate DLK signaling would provide further evidence that DLK activation is a disease-relevant 
process in AD patients. One could test this by asking whether p-MKK4 increases following I2PP2A 
overexpression, PPMT knockdown, treatment with truncated α4, cancerous inhibitor of PP2A 
(cip2A) overexpression, or LCMT-1 knockdown(Park et al., 2018; Shentu et al., 2018; Tanimukai 
et al., 2005; Watkins et al., 2012b). All these manipulations have been observed in AD patient 
brains and have been proposed to contribute to disease pathology through modulation of PP2A 
activity.  
3.3 PP2A targets 
 Here, I have shown that PP2A inhibition increases cortical neuron death independent from 
Tau despite hyperphosphorylation of Tau being one of the best studied consequences of PP2A 
inhibition in neurons. This finding demonstrates that hyperphosphorylated Tau does not affect a 
cell-autonomous apoptosis pathway and that inhibition of DLK is required to block neuronal cell 
death downstream of PP2A inhibition. Our system for assessing cell death only cultured cortical 
neurons, but there is a vast literature demonstrating glial and immune response in AD. Could 
hyperphosphorylated Tau contribute to cell death and disease progression in a non-cell 




also focused on Tau as a single substrate of PP2A and suspect that modulation of a family of MAPs 
is affected. Is it possible to define some of these downstream targets that contribute to DLK 
activation when PP2A is inhibited?  
 The finding that neurons lacking any Tau protein show similar cell death rates to neurons 
with normal levels of Tau protein and an increase in hyperphosphorylated Tau provided paradigm-
shifting evidence that increased Tau phosphorylation is not itself toxic. However, these findings 
must be appreciated in the context of cell-autonomous apoptosis. Tau is not only aggregated 
intracellularly, but also released into the extracellular space where it can be taken up by 
surrounding cells, such as microglia, or contribute to the cell-to-cell spread of pathological Tau 
species(Calafate et al., 2015; Gómez-Ramos et al., 2006; Pooler et al., 2013; Simón et al., 2012). 
Because Tau extends beyond cell-autonomous functions, further testing should demonstrate 
whether neuronal cell death following PP2A inhibition is still Tau-independent in systems better 
representing the brain environment. One could test this using direct injection of PP2A inhibitor 
into the mouse brain or a co-culture system with glial cells in addition to neurons and measuring 
whether Tau knockout affects rates of cell death. If a Tau-dependent cell death process is found, it 
should be examined whether DLK signaling affects such a process. 
 For this study I focused specifically on Tau as a PP2A substrate as it is well-studied and 
disease relevant. However, PP2A targets many substrates, a number of them cytoskeleton-related 
proteins. This provides a basis for further exploration into other DLK-dependent phenotypes 
downstream of dysregulation of these proteins. For example, Doublecortin mutations have been 
shown to cause X-linked lissencephaly. A mutated form of Doublecortin could be expressed in 
Drosophila or cortical neurons to test for DLK activation and whether any phenotypes are DLK-




protein Chromosome Bows (ChB) in Drosophila. ChB is a target of PP2A modulation in other cell 
types and loss of function mutants present with synaptic overgrowth, thus this is a prime candidate 
to test for DLK-dependent phenotypes(Galjart, 2005.; Inoue et al., 2000; Lee et al., 2004; Lemos 
et al., 2000). It is likely that PP2A is modulating a family of cytoskeleton-associated proteins and 
that no single protein will be required for downstream phenotypes in neurons with inhibited PP2A, 
but substrates could provide candidates for a future screen testing for phenotypes that are DLK-
dependent.  
 There are other cytoskeleton-related proteins not as directly related to PP2A that may also 
serve as candidates for a screen of DLK function. Depletion of the microtubule severing protein 
Katanin causes an increase in synaptic bouton number at the larval NMJ, a similar phenotype to 
flies overexpressing DLK/Wnd or mutant for the E3 ubiquitin ligase highwire which targets Wnd 
for degradation(Collins et al., 2006; Yu et al., 2008). Spastin, a related microtubule severing 
protein, is mutated people suffering from hereditary spastic paraplegia. In this degenerative disease 
patients experience weakness and spasticity in their lower limbs as long axon tracts 
degenerate(Fink, 2013). This increased neuronal stress and axon degeneration are candidates for 
DLK-dependent processes. Thus, microtubule severing enzymes present an intriguing set of targets 
for a screen to test if their loss of function triggers an increase in DLK signaling.  
3.4 Conclusion 
 Neurons must survive a lifetime and so have complex signal transduction mechanisms to 
interpret internal and external stressors. PP2A acts to restrain stress signaling through the DLK 
pathway in neurons, both during development and in degenerative disease. The synaptic 
overgrowth at the neuromuscular junction in animals with decreased PP2A activity requires a 




developing neuron as had been previously hypothesized. The discovery of a cell-autonomous 
response headed by DLK provided insight into the mechanism of cell death following neuronal 
PP2A inhibition and defined a target for therapeutic intervention in a devastating disease. Further, 
I demonstrated that Tau is not required for a cell intrinsic apoptotic pathway despite the link 





Akhmanova, A., Steinmetz, M.O., 2015. Control of microtubule organization and dynamics: two 
ends in the limelight. Nat. Rev. | Mol. CELL Biol. 16. https://doi.org/10.1038/nrm4084 
Akhmanova, A., Steinmetz, M.O., 2010. Microtubule +TIPs at a glance. J. Cell Sci. 123, 3415–
3419. https://doi.org/10.1242/jcs.062414 
Alexa, A., Schmidt, G., Tompa, P., Ogueta, S., Vázquez, J., Kulcsár, P., Kovács, J., Dombrádi, 
V., Friedrich, P., 2002. The phosphorylation state of threonine-220, a uniquely phosphatase-
sensitive protein kinase a site in microtubule-associated protein MAP2c, regulates microtubule 
binding and stability. Biochemistry 41, 12427–12435. https://doi.org/10.1021/bi025916s 
Arendt, T., Holzer, M., Fruth, R., Brückner, M.K., Gärtner, U., 1998. Phosphorylation of tau, aβ-
formation, and apoptosis after in vivo inhibition of PP-1 and PP-2A. Neurobiol. Aging 19, 3–13. 
https://doi.org/10.1016/S0197-4580(98)00003-7 
Asghari Adib, E., Smithson, L.J., Collins, C.A., 2018. An axonal stress response pathway: 
degenerative and regenerative signaling by DLK. Curr. Opin. Neurobiol. 
https://doi.org/10.1016/j.conb.2018.07.002 
Baines, A.J., 2010. The spectrin-ankyrin-4.1-adducin membrane skeleton: Adapting eukaryotic 
cells to the demands of animal life. Protoplasma. https://doi.org/10.1007/s00709-010-0181-1 
Bennett, V., Baines, A.J., 2001. Spectrin and ankyrin-based pathways: Metazoan inventions for 
integrating cells into tissues. Physiol. Rev. https://doi.org/10.1152/physrev.2001.81.3.1353 
Brace, E.J., Wu, C., Valakh, V., DiAntonio, A., 2014. SkpA Restrains Synaptic Terminal 
Growth during Development and Promotes Axonal Degeneration following Injury. J. Neurosci. 
34, 8398–8410. https://doi.org/10.1523/JNEUROSCI.4715-13.2014 
Burgess, R.W., Peterson, K.A., Johnson, M.J., Roix, J.J., Welsh, I.C., O’Brien, T.P., 2004. 
Evidence for a conserved function in synapse formation reveals Phr1 as a candidate gene for 
respiratory failure in newborn mice. Mol. Cell. Biol. 24, 1096–105. 
Calafate, S., Buist, A., Miskiewicz, K., Vijayan, V., Daneels, G., de Strooper, B., de Wit, J., 
Verstreken, P., Moechars, D., 2015. Synaptic Contacts Enhance Cell-to-Cell Tau Pathology 
Propagation. Cell Rep. 11, 1176–1183. https://doi.org/10.1016/J.CELREP.2015.04.043 
Chen, J., Martin, B., Brautiganm, D., 1992. Regulation of protein serine-threonine phosphatase 
type-2A by tyrosine phosphorylation. Science 257, 1261–1264. 
https://doi.org/10.1126/SCIENCE.1325671 
Chen, X., Rzhetskaya, M., Kareva, T., Bland, R., During, M.J., Tank, A.W., Kholodilov, N., 
Burke, R.E., 2008. Antiapoptotic and trophic effects of dominant-negative forms of dual leucine 





Collins, C.A., Wairkar, Y.P., Johnson, S.L., DiAntonio, A., 2006. Highwire Restrains Synaptic 
Growth by Attenuating a MAP Kinase Signal. Neuron 51, 57–69. 
https://doi.org/10.1016/j.neuron.2006.05.026 
Cormier, P., Osborne, H.B., Bassez, T., Poulhe, R., Bellé, R., Mulner-Lorillon, O., 1991. Protein 
phosphatase 2A from Xenopus oocytes. Characterization during meiotic cell division. FEBS 
Lett. 295, 185–188. https://doi.org/10.1016/0014-5793(91)81414-4 
Daniels, R.W., Collins, C.A., Gelfand, M. V., Dant, J., Brooks, E.S., Krantz, D.E., DiAntonio, 
A., 2004. Increased expression of the Drosophila vesicular glutamate transporter leads to excess 
glutamate release and a compensatory decrease in quantal content. J. Neurosci. 24, 10466–
10474. https://doi.org/10.1523/JNEUROSCI.3001-04.2004 
Daniels, R.W., Gelfand, M. V, Collins, C.A., DiAntonio, A., 2008. Visualizing glutamatergic 
cell bodies and synapses in Drosophila larval and adult CNS. J. Comp. Neurol. 508, 131–52. 
https://doi.org/10.1002/cne.21670 
Desai, A., Mitchison, T.J., 1997. Microtubule polymerization dynamics. Annu. Rev. Cell Dev. 
Biol. https://doi.org/10.1146/annurev.cellbio.13.1.83 
E, S., A, L., C, H., I, M., E, O., S, S., CL, W., 2004. Altered expression levels of the protein 
phosphatase 2A ABalphaC enzyme are associated with Alzheimer disease pathology. J. 
Neuropathol. Exp. Neurol. 63, 287–301. https://doi.org/10.1093/JNEN/63.4.287 
Eto, K., Kawauchi, T., Osawa, M., Tabata, H., Nakajima, K., 2010. Role of dual leucine zipper-
bearing kinase (DLK/MUK/ZPK) in axonal growth. Neurosci. Res. 66, 37–45. 
https://doi.org/10.1016/J.NEURES.2009.09.1708 
Fernandes, K.A., Harder, J.M., John, S.W., Shrager, P., Libby, R.T., 2014. DLK-dependent 
signaling is important for somal but not axonal degeneration of retinal ganglion cells following 
axonal injury. Neurobiol. Dis. 69, 108–116. https://doi.org/10.1016/j.nbd.2014.05.015 
Figley, M.D., Gu, W., Nanson, J.D., Shi, Y., Sasaki, Y., Cunnea, K., Malde, A.K., Jia, X., Luo, 
Z., Saikot, F.K., Mosaiab, T., Masic, V., Holt, S., Hartley-Tassell, L., McGuinness, H.Y., Manik, 
M.K., Bosanac, T., Landsberg, M.J., Kerry, P.S., Mobli, M., Hughes, R.O., Milbrandt, J., Kobe, 
B., DiAntonio, A., Ve, T., 2021. SARM1 is a metabolic sensor activated by an increased 
NMN/NAD+ ratio to trigger axon degeneration. Neuron 109, 1118-1136.e11. 
https://doi.org/10.1016/j.neuron.2021.02.009 
Fink, J.K., 2013. Hereditary spastic paraplegia: clinico-pathologic features and emerging 
molecular mechanisms. Acta Neuropathol. 2013 1263 126, 307–328. 
https://doi.org/10.1007/S00401-013-1115-8 
Frey, E., Valakh, V., Karney-Grobe, S., Shi, Y., Milbrandt, J., DiAntonio, A., 2015. An in vitro 
assay to study induction of the regenerative state in sensory neurons. Exp. Neurol. 263, 350–363. 
https://doi.org/10.1016/J.EXPNEUROL.2014.10.012 





Gerdts, J., Summers, D.W., Milbrandt, J., DiAntonio, A., 2016. Axon Self-Destruction: New 
Links among SARM1, MAPKs, and NAD+ Metabolism. Neuron. 
https://doi.org/10.1016/j.neuron.2015.12.023 
Ghosh, A.S., Wang, B., Pozniak, C.D., Chen, M., Watts, R.J., Lewcock, J.W., 2011. DLK 
induces developmental neuronal degeneration via selective regulation of proapoptotic JNK 
activity. J. Cell Biol. 194, 751–764. https://doi.org/10.1083/jcb.201103153 
Goel, P., Dickman, D., 2018. Distinct homeostatic modulations stabilize reduced postsynaptic 
receptivity in response to presynaptic DLK signaling. Nat. Commun. 2018 91 9, 1–14. 
https://doi.org/10.1038/s41467-018-04270-0 
Gómez-Ramos, A., Díaz-Hernández, M., Cuadros, R., Hernández, F., Avila, J., 2006. 
Extracellular tau is toxic to neuronal cells. FEBS Lett. 580, 4842–4850. 
https://doi.org/10.1016/J.FEBSLET.2006.07.078 
Gong, C. ‐X, Shaikh, S., Wang, J. ‐Z, Zaidi, T., Grundke‐Iqbal, I., Iqbal, K., 1995. Phosphatase 
Activity Toward Abnormally Phosphorylated τ: Decrease in Alzheimer Disease Brain. J. 
Neurochem. 65, 732–738. https://doi.org/10.1046/j.1471-4159.1995.65020732.x 
Gong, C. ‐X, Singh, T.J., Grundke‐Iqbal, I., Iqbal, K., 1993. Phosphoprotein Phosphatase 
Activities in Alzheimer Disease Brain. J. Neurochem. 61, 921–927. 
https://doi.org/10.1111/j.1471-4159.1993.tb03603.x 
Gong, C.X., Lidsky, T., Wegiel, J., Zuck, L., Grundke-Iqbal, I., Iqbal, K., 2000a. 
Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in 
mammalian brain. Implications for neurofibrillary degeneration in Alzheimer’s disease. J. Biol. 
Chem. 275, 5535–5544. https://doi.org/10.1074/jbc.275.8.5535 
Gong, C.X., Wegiel, J., Lidsky, T., Zuck, L., Avila, J., Wisniewski, H.M., Grundke-Iqbal, I., 
Iqbal, K., 2000b. Regulation of phosphorylation of neuronal microtubule-associated proteins 
MAP1b and MAP2 by protein phosphatase-2A and -2B in rat brain. Brain Res. 853, 299–309. 
https://doi.org/10.1016/S0006-8993(99)02294-5 
Grundke-Iqbal, I., Iqbal, K., Quinlan, M., Tung, Y.C., Zaidi, M.S., Wisniewski, H.M., 1986. 
Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J. Biol. 
Chem. 261, 6084–9. 
Hammarlund, M., Nix, P., Hauth, L., Jorgensen, E.M., Bastiani, M., 2009a. Axon Regeneration 
Requires a Conserved MAP Kinase Pathway. Science (80-. ). 323, 802–806. 
https://doi.org/10.1126/SCIENCE.1165527 
Hammarlund, M., Nix, P., Hauth, L., Jorgensen, E.M., Bastiani, M., 2009b. Axon regeneration 
requires a conserved MAP kinase pathway. Science (80-. ). 323, 802–806. 
https://doi.org/10.1126/science.1165527 
Hannus, M., Feiguin, F., Heisenberg, C.P., Eaton, S., 2002. Planar cell polarization requires 





Hirai, S.-I., DF, C., T, M., M, O., H, K., Y, S., S, A., Y, B., S, O., 2006. The c-Jun N-terminal 
kinase activator dual leucine zipper kinase regulates axon growth and neuronal migration in the 
developing cerebral cortex. J. Neurosci. 26, 11992–12002. 
https://doi.org/10.1523/JNEUROSCI.2272-06.2006 
Holland, S.M., Collura, K.M., Ketschek, A., Noma, K., Ferguson, T.A., Jin, Y., Gallo, G., 
Thomas, G.M., 2016. Palmitoylation controls DLK localization, interactions and activity to 
ensure effective axonal injury signaling. Proc. Natl. Acad. Sci. 113, 763–768. 
https://doi.org/10.1073/PNAS.1514123113 
Honnappa, S., Gouveia, S.M., Weisbrich, A., Damberger, F.F., Bhavesh, N.S., Jawhari, H., 
Grigoriev, I., van Rijssel, F.J.A., Buey, R.M., Lawera, A., Jelesarov, I., Winkler, F.K., Wüthrich, 
K., Akhmanova, A., Steinmetz, M.O., 2009. An EB1-Binding Motif Acts as a Microtubule Tip 
Localization Signal. Cell 138, 366–376. https://doi.org/10.1016/J.CELL.2009.04.065 
Inoue, Y.H., Maria, ‡, Avides, C., Shiraki, M., Deak, P., Yamaguchi, M., Nishimoto, Y., 
Matsukage, A., Glover, D.M., 2000. Orbit, a Novel Microtubule-associated Protein Essential for 
Mitosis in Drosophila melanogaster. J. Cell Biol. 149, 153–165. 
https://doi.org/10.1083/jcb.149.1.153 
Iqbal, K., Liu, F., Gong, C.X., del Alonso, A.C., Grundke-Iqbal, I., 2009. Mechanisms of tau-
induced neurodegeneration. Acta Neuropathol. https://doi.org/10.1007/s00401-009-0486-3 
Janssens, V., Goris, J., 2001. Protein phosphatase 2A: A highly regulated family of 
serine/threonine phosphatases implicated in cell growth and signalling. Biochem. J. 
https://doi.org/10.1042/0264-6021:3530417 
Kamat, P.K., Rai, S., Nath, C., 2013. Okadaic acid induced neurotoxicity: An emerging tool to 
study Alzheimer’s disease pathology. Neurotoxicology. 
https://doi.org/10.1016/j.neuro.2013.05.002 
Kapitein, L.C., Hoogenraad, C.C., 2015. Building the Neuronal Microtubule Cytoskeleton. 
Neuron. https://doi.org/10.1016/j.neuron.2015.05.046 
Karney-Grobe, S., Russo, A., Frey, E., Milbrandt, J., Diantonio, X.A., 2018. HSP90 is a 
chaperone for DLK and is required for axon injury signaling. Proc. Natl. Acad. Sci. U. S. A. 115, 
E9899–E9908. https://doi.org/10.1073/PNAS.1805351115 
Keramidis, I., Vourkou, E., Papanikolopoulou, K., Skoulakis, E.M.C., 2020. Functional 
Interactions of Tau Phosphorylation Sites That Mediate Toxicity and Deficient Learning in 
Drosophila melanogaster. Front. Mol. Neurosci. 13, 191. 
https://doi.org/10.3389/fnmol.2020.569520 
Kim, D., Su, J., Cotman, C.W., 1999a. Sequence of neurodegeneration and accumulation of 
phosphorylated tau in cultured neurons after okadaic acid treatment. Brain Res. 839, 253–262. 
https://doi.org/10.1016/S0006-8993(99)01724-2 
Kim, D., Su, J., Cotman, C.W., 1999b. Sequence of neurodegeneration and accumulation of 





Kins, S., Crameri, A., Evans, D.R.H., Hemmings, B.A., Nitsch, R.M., Götz, J., 2001. Reduced 
Protein Phosphatase 2A Activity Induces Hyperphosphorylation and Altered 
Compartmentalization of Tau in Transgenic Mice. J. Biol. Chem. 276, 38193–38200. 
https://doi.org/10.1074/jbc.m102621200 
Klinedinst, S., Wang, X., Xiong, X., Haenfler, J.M., Collins, C.A., 2013. 
Development/Plasticity/Repair Independent Pathways Downstream of the Wnd/DLK MAPKKK 
Regulate Synaptic Structure, Axonal Transport, and Injury Signaling. 
https://doi.org/10.1523/JNEUROSCI.5160-12.2013 
Kuijpers, M., Hoogenraad, C.C., 2011. Centrosomes, microtubules and neuronal development. 
Mol. Cell. Neurosci. 48, 349–358. https://doi.org/10.1016/J.MCN.2011.05.004 
Le Pichon, C.E., Meilandt, W.J., Dominguez, S., Solanoy, H., Lin, H., Ngu, H., Gogineni, A., 
Sengupta Ghosh, A., Jiang, Z., Lee, S.-H., Maloney, J., Gandham, V.D., Pozniak, C.D., Wang, 
B., Lee, S., Siu, M., Patel, S., Modrusan, Z., Liu, X., Rudhard, Y., Baca, M., Gustafson, A., 
Kaminker, J., Carano, R.A.D., Huang, E.J., Foreman, O., Weimer, R., Scearce-Levie, K., 
Lewcock, J.W., 2017. Loss of dual leucine zipper kinase signaling is protective in animal models 
of neurodegenerative disease. Sci. Transl. Med. 9, eaag0394. 
https://doi.org/10.1126/scitranslmed.aag0394 
Lee, H., Engel, U., Rusch, J., Scherrer, S., Sheard, K., Van Vactor, D., 2004. The microtubule 
plus end tracking protein orbit/MAST/CLASP acts downstream of the tyrosine kinase Abl in 
mediating axon guidance. Neuron 42, 913–926. https://doi.org/10.1016/j.neuron.2004.05.020 
Lemos, C.L., Sampaio, P., Maiato, H., Costa, M., Omel’yanchuk, L. V., Liberal, V., Sunkel, 
C.E., 2000. Mast, a conserved microtubule-associated protein required for bipolar mitotic spindle 
organization. EMBO J. 19, 3668–3682. https://doi.org/10.1093/emboj/19.14.3668 
Liu, F., Grundke-Iqbal, I., Iqbal, K., Gong, C.X., 2005. Contributions of protein phosphatases 
PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur. J. Neurosci. 22, 1942–
1950. https://doi.org/10.1111/j.1460-9568.2005.04391.x 
Loring, J.F., Wen, X., Lee, J.M., Seilhamer, J., Somogyi, R., 2001. A Gene Expression Profile of 
Alzheimer’s Disease. DNA Cell Biol. 20, 683–695. 
Louis, J. V., Martens, E., Borghgraef, P., Lambrecht, C., Sents, W., Longin, S., Zwaenepoel, K., 
Pijnenborg, R., Landrieu, I., Lippens, G., Ledermann, B., Götz, J., Van Leuven, F., Goris, J., 
Janssens, V., 2011. Mice lacking phosphatase PP2A subunit PR61/B′δ (Ppp2r5d) develop 
spatially restricted tauopathy by deregulation of CDK5 and GSK3β. Proc. Natl. Acad. Sci. U. S. 
A. 108, 6957–6962. https://doi.org/10.1073/pnas.1018777108 
Malchiodi-Albedi, F., Petrucci, T.C., Picconi, B., Iosi, F., Falchi, M., 1997. Protein phosphatase 
inhibitors induce modification of synapse structure and tau hyperphosphorylation in cultured rat 





Martín-Blanco, E., Gampel, A., Ring, J., Virdee, K., Kirov, N., Tolkovsky, A.M., Martinez-
Arias, A., 1998. puckered encodes a phosphatase that mediates a feedback loop regulating JNK 
activity during dorsal closure in Drosophila. Genes Dev. 12, 557–70. 
Martin, L., Page, G., Terro, F., 2011. Tau phosphorylation and neuronal apoptosis induced by the 
blockade of PP2A preferentially involve GSK3β. Neurochem. Int. 59, 235–250. 
https://doi.org/10.1016/j.neuint.2011.05.010 
Mcnally, F.J., Roll-Mecak, A., 2018. Microtubule-severing enzymes: From cellular functions to 
molecular mechanism. J. Cell Biol 217, 4057–4069. https://doi.org/10.1083/jcb.201612104 
Merrick, S.E., Trojanowski, J.Q., Lee, V.M.Y., 1997. Selective destruction of stable 
microtubules and axons by inhibitors of protein serine/threonine phosphatases in cultured human 
neurons (NT2N cells). J. Neurosci. 17, 5726–5737. https://doi.org/10.1523/jneurosci.17-15-
05726.1997 
Miller, B.R., Press, C., Daniels, R.W., Sasaki, Y., Milbrandt, J., DiAntonio, A., 2009. A dual 
leucine kinase–dependent axon self-destruction program promotes Wallerian degeneration. Nat. 
Neurosci. 2009 124 12, 387–389. https://doi.org/10.1038/nn.2290 
Nakata, K., Abrams, B., Grill, B., Goncharov, A., Huang, X., Chisholm, A.D., Jin, Y., 2005. 
Regulation of a DLK-1 and p38 MAP Kinase Pathway by the Ubiquitin Ligase RPM-1 Is 
Required for Presynaptic Development. Cell 120, 407–420. 
https://doi.org/10.1016/J.CELL.2004.12.017 
Park, H.J., Lee, K.W., Oh, S., Yan, R., Zhang, J., Beach, T.G., Adler, C.H., Voronkov, M., 
Braithwaite, S.P., Stock, J.B., Mouradian, M.M., 2018. Protein phosphatase 2A and its 
methylation modulating enzymes LCMT-1 and PME-1 are dysregulated in tauopathies of 
progressive supranuclear palsy and Alzheimer disease. J. Neuropathol. Exp. Neurol. 77, 139–
148. https://doi.org/10.1093/jnen/nlx110 
Pielage, J., Bulat, V., Zuchero, J.B., Fetter, R.D., Davis, G.W., 2011. Hts/adducin controls 
synaptic elaboration and elimination. Neuron 69, 1114–1131. 
https://doi.org/10.1016/j.neuron.2011.02.007 
Pielage, J., Cheng, L., Fetter, R.D., Carlton, P.M., Sedat, J.W., Davis, G.W., 2008. A Presynaptic 
Giant Ankyrin Stabilizes the NMJ through Regulation of Presynaptic Microtubules and 
Transsynaptic Cell Adhesion. Neuron 58, 195–209. https://doi.org/10.1016/j.neuron.2008.02.017 
Pielage, J., Fetter, R.D., Davis, G.W., 2005. Presynaptic Spectrin Is Essential for Synapse 
Stabilization. Curr. Biol. 15, 918–928. https://doi.org/10.1016/J.CUB.2005.04.030 
Pooler, A.M., Phillips, E.C., Lau, D.H.W., Noble, W., Hanger, D.P., 2013. Physiological release 
of endogenous tau is stimulated by neuronal activity. EMBO Rep. 14, 389–394. 
https://doi.org/10.1038/EMBOR.2013.15 
Pozniak, C.D., Ghosh, A.S., Gogineni, A., Hanson, J.E., Lee, S.H., Larson, J.L., Solanoy, H., 
Bustos, D., Li, H., Ngu, H., Jubb, A.M., Ayalon, G., Wu, J., Scearce-Levie, K., Zhou, Q., 




for excitotoxicity-induced neuronal degeneration. J. Exp. Med. 210, 2553–2567. 
https://doi.org/10.1084/jem.20122832 
Pozniak, C.D., Sengupta Ghosh, A., Gogineni, A., Hanson, J.E., Lee, S.-H., Larson, J.L., 
Solanoy, H., Bustos, D., Li, H., Ngu, H., Jubb, A.M., Ayalon, G., Wu, J., Scearce-Levie, K., 
Zhou, Q., Weimer, R.M., Kirkpatrick, D.S., Lewcock, J.W., 2013b. Dual leucine zipper kinase is 
required for excitotoxicity-induced neuronal degeneration. J. Exp. Med. 210, 2553–2567. 
https://doi.org/10.1084/JEM.20122832 
Qian, W., Shi, J., Yin, X., Iqbal, K., Grundke-Iqbal, I., Gong, C.-X., Liu, F., 2010. PP2A 
Regulates Tau Phosphorylation Directly and also Indirectly via Activating GSK-3β. J. 
Alzheimer’s Dis. 19, 1221–1229. https://doi.org/10.3233/JAD-2009-1317 
Rolls, M.M., Thyagarajan, P., Feng, C., 2021. Microtubule dynamics in healthy and injured 
neurons. Dev. Neurobiol. https://doi.org/10.1002/dneu.22746 
Roos, J., Hummel, T., Ng, N., Klämbt, C., Davis, G.W., 2000. Drosophila Futsch regulates 
synaptic microtubule organization and is necessary for synaptic growth. Neuron 26, 371–382. 
https://doi.org/10.1016/S0896-6273(00)81170-8 
Russo, A., DiAntonio, A., 2019. Wnd/DLK Is a Critical Target of FMRP Responsible for 
Neurodevelopmental and Behavior Defects in the Drosophila Model of Fragile X Syndrome. 
Cell Rep. 28, 2581-2593.e5. https://doi.org/10.1016/j.celrep.2019.08.001 
Russo, A., Goel, P., Brace, E., Buser, C., Dickman, D., DiAntonio, A., 2019. The E3 ligase 
Highwire promotes synaptic transmission by targeting the NAD-synthesizing enzyme dNmnat. 
EMBO Rep. 20, e46975. https://doi.org/10.15252/EMBR.201846975 
Saito, T., Shima, H., Osawa, Y., Nagao, M., Hemmings, B.A., Kishimoto, T., Hisanaga, S., 
2002. Neurofilament-associated protein phosphatase 2A: Its possible role in preserving 
neurofilaments in filamentous states. Biochemistry 34, 7376–7384. 
https://doi.org/10.1021/BI00022A010 
Schaar, B.T., Kinoshita, K., McConnell, S.K., 2004. Doublecortin Microtubule Affinity Is 
Regulated by a Balance of Kinase and Phosphatase Activity at the Leading Edge of Migrating 
Neurons. Neuron 41, 203–213. https://doi.org/10.1016/S0896-6273(03)00843-2 
Shentu, Y.P., Huo, Y., Feng, X.L., Gilbert, J., Zhang, Q., Liuyang, Z.Y., Wang, X.L., Wang, G., 
Zhou, H., Wang, X.C., Wang, J.Z., Lu, Y.M., Westermarck, J., Man, H.Y., Liu, R., 2018. CIP2A 
Causes Tau/APP Phosphorylation, Synaptopathy, and Memory Deficits in Alzheimer’s Disease. 
Cell Rep. 24, 713–723. https://doi.org/10.1016/j.celrep.2018.06.009 
Shin, J.E., Cho, Y., Beirowski, B., Milbrandt, J., Cavalli, V., DiAntonio, A., 2012a. Dual 
Leucine Zipper Kinase Is Required for Retrograde Injury Signaling and Axonal Regeneration. 
Neuron 74, 1015–1022. https://doi.org/10.1016/j.neuron.2012.04.028 
Shin, J.E., DiAntonio, A., 2011. Highwire Regulates Guidance of Sister Axons in the Drosophila 





Shin, J.E., Ha, H., Kim, Y.K., Cho, Y., DiAntonio, A., 2019. DLK regulates a distinctive 
transcriptional regeneration program after peripheral nerve injury. Neurobiol. Dis. 127, 178–192. 
https://doi.org/10.1016/j.nbd.2019.02.001 
Shin, J.E., Miller, B.R., Babetto, E., Cho, Y., Sasaki, Y., Qayum, S., Russler, E. V, Cavalli, V., 
Milbrandt, J., DiAntonio, A., 2012b. SCG10 is a JNK target in the axonal degeneration pathway. 
Proc. Natl. Acad. Sci. U. S. A. 109, E3696-705. https://doi.org/10.1073/pnas.1216204109 
Simón, D., García-García, E., Royo, F., Falcón-Pérez, J.M., Avila, J., 2012. Proteostasis of tau. 
Tau overexpression results in its secretion via membrane vesicles. FEBS Lett. 586, 47–54. 
https://doi.org/10.1016/J.FEBSLET.2011.11.022 
Snaith, H.A., Armstrong, C.G., Guo, Y., Kaiser, K., Cohen, P.T., 1996. Deficiency of protein 
phosphatase 2A uncouples the nuclear and centrosome cycles and prevents attachment of 
microtubules to the kinetochore in Drosophila microtubule star (mts) embryos - PubMed. J. Cell 
Sci. 3001–3012. 
Sontag, E., Luangpirom, A., Hladik, C., Mudrak, I., Ogris, E., Speciale, S., White, C.L., 2004. 
Altered Expression Levels of the Protein Phosphatase 2A ABαC Enzyme Are Associated with 
Alzheimer Disease Pathology. J. Neuropathol. Exp. Neurol. 63, 287–301. 
https://doi.org/10.1093/jnen/63.4.287 
Sontag, E., Nunbhakdi-Craig, V., Lee, G., Bloom, G.S., Mumby, M.C., 1996. Regulation of the 
phosphorylation state and microtubule-binding activity of tau by protein phosphatase 2A. Neuron 
17, 1201–1207. https://doi.org/10.1016/S0896-6273(00)80250-0 
Sontag, E., Nunbhakdi-Craig, V., Lee, G., Brandt, R., Kamibayashi, C., Kuret, J., White, C.L., 
Mumby, M.C., Bloom, G.S., 1999. Molecular interactions among protein phosphatase 2A, tau, 
and microtubules. Implications for the regulation of tau phosphorylation and the development of 
tauopathies. J. Biol. Chem. 274, 25490–25498. https://doi.org/10.1074/jbc.274.36.25490 
Sontag, J.M., Nunbhakdi-Craig, V., White, C.L., Halpain, S., Sontag, E., 2012. The protein 
phosphatase PP2A/Bα binds to the microtubule-associated proteins Tau and MAP2 at a motif 
also recognized by the kinase Fyn: Implications for tauopathies. J. Biol. Chem. 287, 14984–
14993. https://doi.org/10.1074/jbc.M111.338681 
Sontag, J.M., Sontag, E., 2014. Protein phosphatase 2A dysfunction in Alzheimer’s disease. 
Front. Mol. Neurosci. 7, 16. https://doi.org/10.3389/fnmol.2014.00016 
Strack, S., Westphal, R.S., Colbran, R.J., Ebner, F.F., Wadzinski, B.E., 1997. Protein 
serine/threonine phosphatase 1 and 2A associate with and dephosphorylate neurofilaments. Mol. 
Brain Res. 49, 15–28. https://doi.org/10.1016/S0169-328X(97)00117-4 
Sun, L., Liu, S.Y., Zhou, X.W., Wang, X.C., Liu, R., Wang, Q., Wang, J.Z., 2003. Inhibition of 
protein phosphatase 2A- and protein phosphatase 1-induced tau hyperphosphorylation and 
impairment of spatial memory retention in rats. Neuroscience 118, 1175–1182. 
https://doi.org/10.1016/S0306-4522(02)00697-8 




FEBS Lett. https://doi.org/10.1002/1873-3468.12907 
Tanimukai, H., Grundke-Iqbal, I., Iqbal, K., 2005. Up-Regulation of Inhibitors of Protein 
Phosphatase-2A in Alzheimer’s Disease. Am. J. Pathol. 166, 1761–1771. 
https://doi.org/10.1016/S0002-9440(10)62486-8 
Ulloa, L., Dombrádi, V., Díaz-Nido, J., Szücs, K., Gergely, P., Friedrich, P., Avila, J., 1993. 
Dephosphorylation of distinct sites on microtubule-associated protein MAP1B by protein 
phosphatases 1, 2A and 2B. FEBS Lett. 330, 85–89. https://doi.org/10.1016/0014-
5793(93)80925-K 
Valakh, V., Frey, E., Babetto, E., Walker, L.J., Diantonio, A., 2015a. Cytoskeletal disruption 
activates the DLK/JNK pathway, which promotes axonal regeneration and mimics a 
preconditioning injury HHS Public Access. Neurobiol Dis 77, 13–25. 
https://doi.org/10.1016/j.nbd.2015.02.014 
Valakh, V., Frey, E., Babetto, E., Walker, L.J., DiAntonio, A., 2015b. Cytoskeletal disruption 
activates the DLK/JNK pathway, which promotes axonal regeneration and mimics a 
preconditioning injury. Neurobiol. Dis. 77, 13–25. https://doi.org/10.1016/j.nbd.2015.02.014 
Valakh, V., Naylor, S.A., Berns, D.S., Diantonio, A., 2012. A large-scale RNAi screen identifies 
functional classes of genes shaping synaptic development and maintenance. Dev Biol. Dev Biol. 
June 15, 163–171. https://doi.org/10.1016/j.ydbio.2012.04.008 
Valakh, V., Walker, L.J., Skeath, J.B., DiAntonio, A., 2013. Loss of the Spectraplakin Short 
Stop Activates the DLK Injury Response Pathway in Drosophila. J. Neurosci. 33, 17863. 
https://doi.org/10.1523/JNEUROSCI.2196-13.2013 
Viquez, N.M., Füger, P., Valakh, V., Daniels, R.W., Rasse, T.M., DiAntonio, A., 2009. PP2A 
and GSK-3β act antagonistically to regulate active zone development. J. Neurosci. 29, 11484–
11494. https://doi.org/10.1523/JNEUROSCI.5584-08.2009 
Viquez, N.M., Li, C.R., Wairkar, Y.P., DiAntonio, A., 2006. The B′ protein phosphatase 2A 
regulatory subunit well-rounded regulates synaptic growth and cytoskeletal stability at the 
Drosophila neuromuscular junction. J. Neurosci. 26, 9293–9303. 
https://doi.org/10.1523/JNEUROSCI.1740-06.2006 
Vogelsberg-Ragaglia, V., Schuck, T., Trojanowski, J.Q., Lee, V.M.Y., 2001a. PP2A mRNA 
expression is quantitatively decreased in Alzheimer’s disease hippocampus. Exp. Neurol. 168, 
402–412. https://doi.org/10.1006/exnr.2001.7630 
Vogelsberg-Ragaglia, V., Schuck, T., Trojanowski, J.Q., Lee, V.M.Y., 2001b. PP2A mRNA 
Expression Is Quantitatively Decreased in Alzheimer’s Disease Hippocampus. Exp. Neurol. 168, 
402–412. https://doi.org/10.1006/EXNR.2001.7630 
Walker, L.J., Summers, D.W., Sasaki, Y., Brace, E.J., Milbrandt, J., DiAntonio, A., 2017. 
MAPK signaling promotes axonal degeneration by speeding the turnover of the axonal 




Wan, H.I., DiAntonio, A., Fetter, R.D., Bergstrom, K., Strauss, R., Goodman, C.S., 2000. 
Highwire regulates synaptic growth in Drosophila. Neuron 26, 313–329. 
https://doi.org/10.1016/S0896-6273(00)81166-6 
Wang, G., Simon, D.J., Wu, Z., Belsky, D.M., Heller, E., O’Rourke, M.K., Hertz, N.T., Molina, 
H., Zhong, G., Tessier-Lavigne, M., Zhuang, X., 2019. Structural plasticity of actin-spectrin 
membrane skeleton and functional role of actin and spectrin in axon degeneration. Elife 8. 
https://doi.org/10.7554/ELIFE.38730 
Watkins, G.R., Wang, N., Mazalouskas, M.D., Gomez, R.J., Guthrie, C.R., Kraemer, B.C., 
Schweiger, S., Spiller, B.W., Wadzinski, B.E., 2012a. Monoubiquitination promotes calpain 
cleavage of the protein phosphatase 2A (PP2A) regulatory subunit α4, altering PP2A stability 
and microtubule-associated protein phosphorylation. J. Biol. Chem. 287, 24207–24215. 
https://doi.org/10.1074/jbc.M112.368613 
Watkins, G.R., Wang, N., Mazalouskas, M.D., Gomez, R.J., Guthrie, C.R., Kraemer, B.C., 
Schweiger, S., Spiller, B.W., Wadzinski, B.E., 2012b. Monoubiquitination Promotes Calpain 
Cleavage of the Protein Phosphatase 2A (PP2A) Regulatory Subunit α4, Altering PP2A Stability 
and Microtubule-associated Protein Phosphorylation. J. Biol. Chem. 287, 24207–24215. 
https://doi.org/10.1074/JBC.M112.368613 
Watkins, T.A., Wang, B., Huntwork-Rodriguez, S., Yang, J., Jiang, Z., Eastham-Anderson, J., 
Modrusan, Z., Kaminker, J.S., Tessier-Lavigne, M., Lewcock, J.W., 2013. DLK initiates a 
transcriptional program that couples apoptotic and regenerative responses to axonal injury. Proc. 
Natl. Acad. Sci. U. S. A. 110, 4039–44. https://doi.org/10.1073/pnas.1211074110 
Welsbie, D.S., Yang, Z., Ge, Y., Mitchell, K.L., Zhou, X., Martin, S.E., Berlinicke, C.A., 
Hackler, L., Fuller, J., Fu, J., Cao, L.H., Han, B., Auld, D., Xue, T., Hirai, S.I., Germain, L., 
Simard-Bisson, C., Blouin, R., Nguyen, J. V., Davis, C.H.O., Enke, R.A., Boye, S.L., Merbs, 
S.L., Marsh-Armstrong, N., Hauswirth, W.W., Diantonio, A., Nickells, R.W., Inglese, J., Hanes, 
J., Yau, K.W., Quigley, H.A., Zack, D.J., 2013. Functional genomic screening identifies dual 
leucine zipper kinase as a key mediator of retinal ganglion cell death. Proc. Natl. Acad. Sci. U. S. 
A. 110, 4045–4050. https://doi.org/10.1073/pnas.1211284110 
Welsbie, D.S., Ziogas, N.K., Xu, L., Kim, B.-J., Ge, Y., Patel, A.K., Ryu, J., Lehar, M., 
Alexandris, A.S., Stewart, N., Zack, D.J., Koliatsos, V.E., 2019. Targeted disruption of dual 
leucine zipper kinase and leucine zipper kinase promotes neuronal survival in a model of diffuse 
traumatic brain injury. Mol. Neurodegener. 2019 141 14, 1–18. https://doi.org/10.1186/S13024-
019-0345-1 
Xiong, X., Hao, Y., Sun, K., Li, J., Li, X., Mishra, B., Soppina, P., Wu, C., Hume, R.I., Collins, 
C.A., 2012. The Highwire Ubiquitin Ligase Promotes Axonal Degeneration by Tuning Levels of 
Nmnat Protein. PLoS Biol. 10, 1–18. https://doi.org/10.1371/journal.pbio.1001440 
Xiong, X., Wang, X., Ewanek, R., Bhat, P., DiAntonio, A., Collins, C.A., 2010a. Protein 
turnover of the Wallenda/DLK kinase regulates a retrograde response to axonal injury. J. Cell 
Biol. 191, 211–223. https://doi.org/10.1083/jcb.201006039 




turnover of the Wallenda/DLK kinase regulates a retrograde response to axonal injury. J. Cell 
Biol. 191, 211–223. https://doi.org/10.1083/JCB.201006039 
Xu, K., Zhong, G., Zhuang, X., 2013. Actin, spectrin and associated proteins form a periodic 
cytoskeletal structure in axons. Science 339, 452–456. 
https://doi.org/10.1126/SCIENCE.1232251 
Yan, D., Wu, Z., Chisholm, A.D., Jin, Y., 2009. The DLK-1 Kinase Promotes mRNA Stability 
and Local Translation in C. elegans Synapses and Axon Regeneration. Cell 138, 1005–1018. 
https://doi.org/10.1016/j.cell.2009.06.023 
Yao, K.M., White, K., 1994. Neural specificity of elav expression: Defining a Drosophila 
promoter for directing expression to the nervous system. J. Neurochem. 63, 41–51. 
https://doi.org/10.1046/j.1471-4159.1994.63010041.x 
Yin, C., Huang, G. fu, Sun, X. chuan, Guo, Z., Zhang, J.H., 2017. DLK silencing attenuated 
neuron apoptosis through JIP3/MA2K7/JNK pathway in early brain injury after SAH in rats. 
Neurobiol. Dis. 103, 133–143. https://doi.org/10.1016/j.nbd.2017.04.006 
Yu, W., Qiang, L., Solowska, J.M., Karabay, A., Korulu, S., Baas, P.W., 2008. The microtubule-
severing proteins spastin and katanin participate differently in the formation of axonal branches. 
Mol. Biol. Cell 19, 1485–1498. https://doi.org/10.1091/mbc.E07-09-0878 
Zhan, L., Xie, Q., Tibbetts, R.S., 2015. Opposing roles of p38 and JNK in a Drosophila model of 
TDP-43 proteinopathy reveal oxidative stress and innate immunity as pathogenic components of 
neurodegeneration. Hum. Mol. Genet. 24, 757–772. https://doi.org/10.1093/HMG/DDU493 
 
